EP2462225B1 - Verfahren zur effizienten herstellung induzierter pluripotenter stammzellen - Google Patents
Verfahren zur effizienten herstellung induzierter pluripotenter stammzellen Download PDFInfo
- Publication number
- EP2462225B1 EP2462225B1 EP10806584.8A EP10806584A EP2462225B1 EP 2462225 B1 EP2462225 B1 EP 2462225B1 EP 10806584 A EP10806584 A EP 10806584A EP 2462225 B1 EP2462225 B1 EP 2462225B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- cell
- pcxle
- nucleic acid
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 84
- 210000004263 induced pluripotent stem cell Anatomy 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims description 530
- 239000013598 vector Substances 0.000 claims description 162
- 241000282414 Homo sapiens Species 0.000 claims description 129
- 102000039446 nucleic acids Human genes 0.000 claims description 106
- 108020004707 nucleic acids Proteins 0.000 claims description 106
- 230000008672 reprogramming Effects 0.000 claims description 106
- 150000007523 nucleic acids Chemical class 0.000 claims description 105
- 108020004414 DNA Proteins 0.000 claims description 94
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 79
- 239000004055 small Interfering RNA Substances 0.000 claims description 71
- 239000000126 substance Substances 0.000 claims description 68
- 210000001082 somatic cell Anatomy 0.000 claims description 61
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims description 56
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 55
- 101150086694 SLC22A3 gene Proteins 0.000 claims description 53
- 239000003112 inhibitor Substances 0.000 claims description 51
- 108020004459 Small interfering RNA Proteins 0.000 claims description 45
- 101150111214 lin-28 gene Proteins 0.000 claims description 37
- 239000000470 constituent Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 10
- 230000010076 replication Effects 0.000 claims description 10
- 230000006698 induction Effects 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 159
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 159
- 108090000623 proteins and genes Proteins 0.000 description 133
- 239000002609 medium Substances 0.000 description 75
- 239000013612 plasmid Substances 0.000 description 66
- 238000012546 transfer Methods 0.000 description 59
- 210000002950 fibroblast Anatomy 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 41
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 33
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 32
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 30
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 28
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 28
- 239000013604 expression vector Substances 0.000 description 28
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 26
- -1 Nanog Proteins 0.000 description 25
- 239000012894 fetal calf serum Substances 0.000 description 25
- 210000000130 stem cell Anatomy 0.000 description 25
- 238000001890 transfection Methods 0.000 description 23
- 239000013600 plasmid vector Substances 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 210000000349 chromosome Anatomy 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 239000013603 viral vector Substances 0.000 description 18
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 17
- 230000000692 anti-sense effect Effects 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 16
- 241001430294 unidentified retrovirus Species 0.000 description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 15
- 229910052760 oxygen Inorganic materials 0.000 description 15
- 239000001301 oxygen Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 14
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 14
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 230000004069 differentiation Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 239000005090 green fluorescent protein Substances 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 13
- 241000220317 Rosa Species 0.000 description 13
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 13
- 230000010354 integration Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- 210000005258 dental pulp stem cell Anatomy 0.000 description 12
- 238000012423 maintenance Methods 0.000 description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 11
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 11
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 11
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 11
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 11
- 241000713666 Lentivirus Species 0.000 description 11
- 230000002500 effect on skin Effects 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 206010021143 Hypoxia Diseases 0.000 description 10
- 108090000631 Trypsin Proteins 0.000 description 10
- 102000004142 Trypsin Human genes 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000001146 hypoxic effect Effects 0.000 description 10
- 108700025694 p53 Genes Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 239000012588 trypsin Substances 0.000 description 10
- 102000053642 Catalytic RNA Human genes 0.000 description 9
- 108090000994 Catalytic RNA Proteins 0.000 description 9
- 108010051219 Cre recombinase Proteins 0.000 description 9
- 108020005091 Replication Origin Proteins 0.000 description 9
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 9
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 230000001177 retroviral effect Effects 0.000 description 9
- 108091092562 ribozyme Proteins 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 8
- 239000013000 chemical inhibitor Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 238000011835 investigation Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 101150099612 Esrrb gene Proteins 0.000 description 7
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 7
- 238000012744 immunostaining Methods 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 208000005623 Carcinogenesis Diseases 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 6
- 101710128836 Large T antigen Proteins 0.000 description 6
- 101100462520 Mus musculus Tp53 gene Proteins 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 6
- 206010043276 Teratoma Diseases 0.000 description 6
- 230000036952 cancer formation Effects 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000005304 joining Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 229960004857 mitomycin Drugs 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 101150033269 ESRRG gene Proteins 0.000 description 5
- 108010067770 Endopeptidase K Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108091081021 Sense strand Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 210000004700 fetal blood Anatomy 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- HAGVCKULCLQGRF-UHFFFAOYSA-N pifithrin Chemical compound [Br-].C1=CC(C)=CC=C1C(=O)CN1[C+](N)SC2=C1CCCC2 HAGVCKULCLQGRF-UHFFFAOYSA-N 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 4
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 4
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 4
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 4
- 241000711408 Murine respirovirus Species 0.000 description 4
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 description 4
- 101100042680 Mus musculus Slc7a1 gene Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000009454 functional inhibition Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 102000008730 Nestin Human genes 0.000 description 3
- 108010088225 Nestin Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 3
- 101150081664 PAX6 gene Proteins 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 108091030071 RNAI Proteins 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 241000251131 Sphyrna Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 210000005055 nestin Anatomy 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- NXPCMOGORSWOLH-UHFFFAOYSA-N 2-(2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-nitrophenyl)ethanone;hydrobromide Chemical compound Br.C1=CC([N+](=O)[O-])=CC=C1C(=O)CN1C(=N)SC2=C1CCCC2 NXPCMOGORSWOLH-UHFFFAOYSA-N 0.000 description 2
- XMFNSEDROOHGBY-UHFFFAOYSA-N 2-(4-nitrophenyl)-5,6,7,8-tetrahydroimidazo[2,1-b][1,3]benzothiazole Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=CN(C2=C(CCCC2)S2)C2=N1 XMFNSEDROOHGBY-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
- 241000702191 Escherichia virus P1 Species 0.000 description 2
- 102100038000 F-box only protein 15 Human genes 0.000 description 2
- 108091007133 FBXO15 Proteins 0.000 description 2
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 108010058607 HLA-B Antigens Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 2
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 2
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 2
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 2
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 description 2
- 101000777245 Homo sapiens Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100020824 Serine-protein kinase ATM Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 description 2
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000053563 human MYC Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007852 inverse PCR Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000001988 somatic stem cell Anatomy 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- JUNHQBJCWZVSAT-BQYQJAHWSA-N (e)-n-hydroxy-3-[1-methyl-4-(4-methylbenzoyl)pyrrol-2-yl]prop-2-enamide Chemical compound C1=CC(C)=CC=C1C(=O)C1=CN(C)C(\C=C\C(=O)NO)=C1 JUNHQBJCWZVSAT-BQYQJAHWSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- OLTZHXYLLRJLST-UHFFFAOYSA-N 2-(2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethanone Chemical compound C1=CC(C)=CC=C1C(=O)CN1C(=N)SC2=C1CCCC2 OLTZHXYLLRJLST-UHFFFAOYSA-N 0.000 description 1
- IMUKUMUNZJILCG-UHFFFAOYSA-N 2-(4-methylphenyl)-5,6,7,8-tetrahydroimidazo[2,1-b][1,3]benzothiazole Chemical compound C1=CC(C)=CC=C1C1=CN(C2=C(CCCC2)S2)C2=N1 IMUKUMUNZJILCG-UHFFFAOYSA-N 0.000 description 1
- SGNCOAOESGSEOP-UHFFFAOYSA-N 2-(4-methylphenyl)-5,6,7,8-tetrahydroimidazo[2,1-b][1,3]benzothiazole;hydrobromide Chemical compound Br.C1=CC(C)=CC=C1C1=CN(C2=C(CCCC2)S2)C2=N1 SGNCOAOESGSEOP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- ZZUZYEMRHCMVTB-UHFFFAOYSA-N 2-phenylethynesulfonamide Chemical compound NS(=O)(=O)C#CC1=CC=CC=C1 ZZUZYEMRHCMVTB-UHFFFAOYSA-N 0.000 description 1
- VIBDVOOELVZGDU-UHFFFAOYSA-N 4-(1h-indol-2-yl)benzene-1,3-dicarboximidamide Chemical compound NC(=N)C1=CC(C(=N)N)=CC=C1C1=CC2=CC=CC=C2N1 VIBDVOOELVZGDU-UHFFFAOYSA-N 0.000 description 1
- GEBBCNXOYOVGQS-BNHYGAARSA-N 4-amino-1-[(2r,3r,4s,5s)-3,4-dihydroxy-5-(hydroxyamino)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](NO)O1 GEBBCNXOYOVGQS-BNHYGAARSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 101100342337 Caenorhabditis elegans klf-1 gene Proteins 0.000 description 1
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101100248440 Danio rerio ric8b gene Proteins 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 108050002085 Fibroblast growth factor 20 Proteins 0.000 description 1
- 102100031361 Fibroblast growth factor 20 Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 101150072501 Klf2 gene Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 101150107363 Lif gene Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 1
- 101100404103 Mus musculus Nanog gene Proteins 0.000 description 1
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 1
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 1
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 1
- 101150012532 NANOG gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100029566 Rattus norvegicus Rabggta gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101150024531 Slc7a1 gene Proteins 0.000 description 1
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 1
- 101150001847 Sox15 gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100039362 Transducin-like enhancer protein 1 Human genes 0.000 description 1
- 101710101305 Transducin-like enhancer protein 1 Proteins 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 description 1
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 108700020987 Wnt-1 Proteins 0.000 description 1
- 102000052547 Wnt-1 Human genes 0.000 description 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 230000001155 adrenomedullary effect Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 229960005263 bucladesine Drugs 0.000 description 1
- 108010025307 buforin II Proteins 0.000 description 1
- 239000000801 calcium channel stimulating agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 description 1
- 210000003317 double-positive, alpha-beta immature T lymphocyte Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- 108091072810 miR-294 stem-loop Proteins 0.000 description 1
- 108091076076 miR-295 stem-loop Proteins 0.000 description 1
- 108091030789 miR-302 stem-loop Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- FMURUEPQXKJIPS-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C=12C=C(OC)C(OC)=CC2=NC(N2CCN(C)CCC2)=NC=1NC(CC1)CCN1CC1=CC=CC=C1 FMURUEPQXKJIPS-UHFFFAOYSA-N 0.000 description 1
- DOBKQCZBPPCLEG-UHFFFAOYSA-N n-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NC=2N=CN=CC=2)=NC=1C(=O)NCC1=CC=CC=C1 DOBKQCZBPPCLEG-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008684 selective degradation Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000003172 sustentacular cell Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/608—Lin28
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1361—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from dental pulp or dental follicle stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Definitions
- the present invention relates to a method of efficiently establishing an artificial pluripotent stem (hereinafter referred to as iPS) cell and a reagent therefor, more specifically to a method of producing an iPS cell by bringing (a) Oct3/4 or a nucleic acid that encodes the same, (b) Klf4 or a nucleic acid that encodes the same, (c) Sox2 or a nucleic acid that encodes the same, (d) L-Myc or a nucleic acid that encodes the same, (e) a functional inhibitor of p53, and (f) Lin 28 or Lin 28b or a nucleic acid that encodes the same, into contact with a somatic cell in vitro, and to an iPS cell induction promoting agent comprising (a) to (f), as defined by the appended claims.
- iPS artificial pluripotent stem
- an episomal vector comprising the nucleic acid factors of (a) to (c) above, as well as the nucleic acid factors of (d) and/or (e), or a vector which is a combination of the episomal vector and a loxP sequence, particularly to an episomal vector of the early self-removal type, and a method of quickly establishing an iPS cell deprived of an exogenous nucleic acid factor without undergoing the integration of the nucleic acid factor in the genome using the episomal vector.
- Yamanaka et al. induced iPS cells by introducing the Oct3/4, Sox2, Klf4 and c-Myc genes into fibroblasts derived from a mouse, and forcing the cells to express the genes [ WO 2007/069666 A1 ; Takahashi, K. and Yamanaka, S., Cell, 126: 663-676 (2006 )]. Thereafter, it was revealed that iPS cells could also be produced with 3 factors other than the c-Myc gene [ Nakagawa, M. et al., Nat. Biotechnol., 26: 101-106 (2008 )]. Furthermore, Yamanaka et al.
- the efficiency of iPS cell establishment is low at less than 1%.
- a problem of extremely low efficiency of iPS cell establishment occurs when they are produced by introducing 3 factors (Oct3/4, Sox2 and Klf4) other than c-Myc, which is feared to cause tumorigenesis in tissues or individuals differentiated from iPS cells, into somatic cells.
- Viral vectors such as retroviruses and lentiviruses offer higher transfection efficiency than non-viral vectors, and are therefore favorable in that they enable easier generation of iPS cells.
- retroviruses and lentiviruses become integrated in the chromosome, posing a problem with safety in view of the clinical application of iPS cells.
- iPS cells generated using adenovirus vectors or non-viral vectors such as plasmids without vector integration in the chromosome have been reported [ Stadtfeld, M. et al., Science, 322: 945-949 (2008 ); Okita, K. et al., Science, 322: 949-953 (2008 ); Yu, J.
- WO 2009/057831 relates to a process for generating induced pluripotent stem cells comprising the use of Oct, Klf and Sox family genes.
- WOLTJEN K. ET AL., NATURE, (April 2009), vol. 458, no. 7239, pages 766 - 770 describe the use of piggybac transposons to reprogram fibroblasts to induced pluripotent stem cells.
- SWISTOWSKI A. ET AL., E6233, PLOS ONE, (July 2009), vol. 4, no. 7 disclose xeno-free defined conditions for the culture of human embryonic stem cells.
- the present invention is directed to efficiently establishing a safe human iPS cell suitable for clinical application, as defined in the appended claims. Accordingly, it is a first object of the present invention to provide a means to improve the efficiency of establishment of iPS cells, particularly human iPS cells, and a method of efficiently producing an iPS cell by using the means. It is a second object of the present invention to provide a method of quickly establishing an iPS cell that has lost exogenous nucleic acid factors without undergoing the integration of the nucleic acid factors in the genome.
- the present inventors first investigated to find suitable combinations of reprogramming genes using a retroviral vector. Based on the 6 factors used by Yu, J. et al. for establishing a human iPS cell using an episomal vector [Oct3/4, Klf4, c-Myc, Sox2, Nanog, Lin28 (SV40 Large T antigen handled as an establishment efficiency improver, and excluded from the reprogramming genes)] [ Science, 324: 797-801 (2009 )], the present inventors attempted to induce a human iPS cell from a human dermal fibroblast (HDF) using 5 factors except Nanog, or using 5 factors except Nanog, which include L-Myc in place of c-Myc.
- HDF human dermal fibroblast
- a human iPS cell was established more efficiently with the use of the 5 factors other than Nanog than with the 6 factors. Furthermore, as a result of replacement of c-Myc with L-Myc, the establishment efficiency improved remarkably. Hence, human iPS cell establishment efficiency was actually compared between the use of the 6 factors and the use of the 5 factors including L-Myc in place of c-Myc, using an episomal vector. As a result, it was found that the establishment efficiency increased remarkably with the use of the 5 factors including L-Myc in place of c-Myc, compared with the 6 factors.
- iPS cells were obtained with the use of the 6 factors to similar extent compared with the 5 factors including L-Myc in place of c-Myc.
- the establishment efficiency increased still more remarkably. It was also found that by using mouse embryonic fibroblasts (MEF), rather than SNL cells, as feeder cells at the time of passage of HDF after transfection, the human iPS cell establishment efficiency improved dramatically.
- the present inventors had designed the episomal vector to allow a constituent thereof essential for the self-replication thereof to be cut out therefrom by the action of Cre recombinase with a loxP sequence placed at both ends of the vector constituent so as to allow the transferred episomal vector to be shed from the iPS cell quickly after establishment of the iPS cell.
- the cell's genomic DNA and extrachromosomal DNA were isolated and separately examined for the presence or absence of the transgenes.
- the transferred vector was not detected in either DNA; unexpectedly, the vector was found to be an early self-removal vector quickly shedding from the cell, without using Cre recombinase.
- the present inventors succeeded in generating a human iPS cell under completely virus-free and xeno-free conditions from reprogramming factor transfer to iPS cell establishment and maintenance culture, using the above-described episomal vector.
- the present inventors found that human iPS cell establishment efficiency can be improved remarkably by excluding Nanog from the reprogramming factors and using L-Myc in place of c-Myc, or using a functional inhibitor of p53 in place thereof, or in addition thereto, that an iPS cell that has lost exogenous nucleic acid factors without undergoing the integration of the nucleic acid factors in the genome can be acquired quickly by elaborating the design of an episomal vector, and that a human iPS cell can be generated under virus-free and xeno-free conditions by combining the above-described reprogramming factors and episomal vector, and have developed the present invention.
- the present invention provides:
- L-Myc in place of c-Myc and use of a functional inhibitor of p53, as well as the non-use of Nanog, makes it possible to increase iPS cell establishment efficiency remarkably, and is therefore particularly useful in generating a human iPS cell, particularly a human iPS cell of the type that does not involve the integration of reprogramming genes in the genome, with the use of 6 factors that have been extremely low in establishment efficiency (Oct3/4, Klf4, Sox2, c-Myc, Nanog, Lin28).
- an independently developed episomal vector makes it possible to establish an iPS cell without involving the integration of exogenous nucleic acid factors in the genome, and to cause the episome to be shed quickly from the iPS cell after establishment thereof, whereby the vector can be shed from the cell earlier than conventional episomal vectors.
- a human iPS cell can be generated under completely virus-free and xeno-free conditions during the period from reprogramming factor transfer to iPS cell establishment and maintenance, the method of the present invention is highly useful in applying human iPS cells to regenerative medicine.
- epi-iPS cells or "epi-iPSCs” in the present specification.
- the present invention provides a method of producing an iPS cell as defined in the appended claim 1, 2 and 4-14.
- any cells other than germ cells of mammalian origin can be used as starting material for the production of iPS cells.
- Examples include keratinizing epithelial cells (e.g., keratinized epidermal cells), mucosal epithelial cells (e.g., epithelial cells of the superficial layer of tongue), exocrine gland epithelial cells (e.g., mammary gland cells), hormone-secreting cells (e.g., adrenomedullary cells), cells for metabolism or storage (e.g., liver cells), intimal epithelial cells constituting interfaces (e.g., type I alveolar cells), intimal epithelial cells of the obturator canal (e.g., vascular endothelial cells), cells having cilia with transporting capability (e.g., airway epithelial cells), cells for extracellular matrix secretion (e.g., fibro
- undifferentiated progenitor cells include tissue stem cells (somatic stem cells) such as nerve stem cells, hematopoietic stem cells, mesenchymal stem cells, adipose-derived stromal (stem) cells and dental pulp stem cells.
- tissue stem cells such as nerve stem cells, hematopoietic stem cells, mesenchymal stem cells, adipose-derived stromal (stem) cells and dental pulp stem cells.
- tissue stem cells such as nerve stem cells, hematopoietic stem cells, mesenchymal stem cells, adipose-derived stromal (stem) cells and dental pulp stem cells.
- Hematopoietic and mesenchymal stem cells are abundantly contained in bone marrow, umbilical cord blood and placenta. Since bone marrow, umbilical cord bloods and placenta have been deposited into many blood banks, both public and private, and used for the treatment of blood diseases such as leukemia, such deposited
- umbilical cord bloods can be easily collected from umbilical cords obtained at the time of childbirth
- hematopoietic and mesenchymal stem cells obtained from umbilical cord bloods are preferable sources of somatic cells for iPS cell banks.
- Dental pulp stem cells are also expected to serve a source of somatic cells for iPS cell banks, since they are easily available as isolated and prepared from wisdom teeth and other teeth extracted for the treatment of periodontal disease and the like.
- Examples of finally differentiated mature cells include peripheral blood mononuclear cells such as T cells and B cells. Sampling of peripheral blood is a minimally invasive and routinely performed in clinical assays. Since a small volume of peripheral blood samples left unused after clinical assays are usually discarded, they are preferable sources of somatic cells for iPS cell banks. In particular, since T cells can be expanded in vitro with relative ease, iPS cells can be established from even a small volume of peripheral blood samples.
- the choice of mammal individual as a source of somatic cells is not particularly limited; however, when the iPS cells obtained are to be used for regenerative medicine in humans, it is preferable, from the viewpoint of prevention of graft rejection, to collect the somatic cells from a patient or another person with the same or substantially the same HLA type as that of the patient.
- "Substantially the same HLA type" as used herein means that the HLA type of donor matches with that of patient to the extent that the transplanted cells, which have been obtained by inducing differentiation of iPS cells derived from the donor's somatic cells, can be engrafted when they are transplanted to the patient with use of immunosuppressant and the like.
- HLA-A the three major loci of HLA-A, HLA-B and HLA-DR, the four major loci further including HLA-Cw
- major HLAs e.g., the three major loci of HLA-A, HLA-B and HLA-DR, the four major loci further including HLA-Cw
- HLA-Cw the four major loci further including HLA-Cw
- the iPS cells obtained are not to be administered (transplanted) to a human, but used as, for example, a source of cells for screening for evaluating a patient's drug susceptibility or adverse reactions, it is likewise desired to collect the somatic cells from the patient or another person with the same genetic polymorphism correlating with the drug susceptibility or adverse reactions.
- Somatic cells isolated from a mammal can be pre-cultured using a medium known per se suitable for their cultivation according to the choice of cells before being subjected to the step of nuclear reprogramming.
- a medium known per se suitable for their cultivation include, but are not limited to, minimal essential medium (MEM) containing about 5 to 20% fetal calf serum (FCS), Dulbecco's modified Eagle medium (DMEM), RPMI1640 medium, 199 medium, F12 medium, and the like.
- MEM minimal essential medium
- FCS fetal calf serum
- DMEM Dulbecco's modified Eagle medium
- RPMI1640 medium 199 medium
- F12 medium and the like.
- a dental pulp stem cell for example, it is preferable to use a medium for mesenchymal stem cells, such as the Mesenchymal Stem Cell Basal Medium (Lonza).
- a transfer reagent such as cationic liposome, for example, is used in bringing the somatic cell into contact with nuclear reprogramming substances and a functional inhibitor of p53 (and another iPS cell establishment efficiency improver if required), it is sometimes preferable that the medium have been replaced with a serum-free medium so as to prevent the transfer efficiency from decreasing.
- a medium that does not contain any ingredients derived from non-human animals such as FCS
- Media comprising a basal medium supplemented with human-derived ingredients suitable for cultivation of various somatic cells (particularly, recombinant human proteins such as growth factors), non-essential amino acids, vitamins and the like are commercially available; those skilled in the art are able to choose an appropriate xeno-free medium according to the source of somatic cells.
- Somatic cells pre-cultured using a xeno-free medium are dissociated from the culture vessel using an appropriate xeno-free cell dissociation solution, and recovered, after which they are brought into contact with nuclear reprogramming substances and a functional inhibitor of p53.
- a nuclear reprogramming substance can be a proteinous factor(s) capable of inducing an iPS cell from a somatic cell or a nucleic acid that encodes the same (including forms integrated in a vector).
- the nuclear reprogramming substances used in the present invention consist of at least (a) Oct3/4 or a nucleic acid that encodes the same, (b) K1f4 or a nucleic acid that encodes the same, (c) Sox2 or a nucleic acid that encodes the same, (d) L-Myc or a nucleic acid that encoded the same, and (f) L in 28 or L in 28b or a nucleic acid that encodes the same, and additionnaly (e) a functional inhibitor of p53 is used, as defined by the appended claims.
- L-Myc or a nucleic acid that encodes the same, and Lin28 or Lin28b or a nucleic acid that encodes the same, are combined as additional nuclear reprogramming substances.
- the nuclear reprogramming substances used in the present invention exclude Nanog or a nucleic acid that encodes the same.
- the nuclear reprogramming substances used are exemplified by the following combinations (here, only the names for proteinous factors are shown):
- Lin28b can be used in place of Lin28.
- Klf4 may be used in combination therewith.
- any combination that does not fall in (1) to (22) above but comprises all the constituents of any one of (1) to (22) and further comprises an optionally chosen other substance can also be included in the scope of "nuclear reprogramming substances" as used herein.
- the somatic cell to undergo nuclear reprogramming is endogenously expressing one or more of the constituents of any one of (1) to (22) above at a level sufficient to cause nuclear reprogramming, a combination of only the remaining constituents excluding the one or more constituents can also be included in the scope of "nuclear reprogramming substances" according to the present disclosure.
- 5 factors consisting of Oct3/4, Sox2, Klf4, Lin28 (Lin28b) and L-Myc are nuclear reprogramming substances used according to the invention. Also preferred are 6 factors consisting of the above 5 factors and additional SV40 Large T antigen.
- a proteinous factor for use as a nuclear reprogramming substance can be prepared by inserting the cDNA obtained into an appropriate expression vector, introducing the vector into a host cell, and recovering the recombinant proteinous factor from the cultured cell or its conditioned medium.
- the nuclear reprogramming substance used is a nucleic acid that encodes a proteinous factor
- the cDNA obtained is inserted into a viral vector, plasmid vector, episomal vector etc. to construct an expression vector, and the vector is subjected to the step of nuclear reprogramming.
- Transfer of a nuclear reprogramming substance to a somatic cell can be achieved using a method known per se for protein transfer into a cell, provided that the substance is a proteinous factor.
- Such methods include, for example, the method using a protein transfer reagent, the method using a protein transfer domain (PTD)- or cell penetrating peptide (CPP)- fusion protein, the microinjection method and the like.
- Protein transfer reagents are commercially available, including those based on a cationic lipid, such as BioPOTER Protein Delivery Reagent (Gene Therapy Systems), Pro-JectTM Protein Transfection Reagent (PIERCE) and ProVectin (IMGENEX); those based on a lipid, such as Profect-1 (Targeting Systems); those based on a membrane-permeable peptide, such as Penetrain Peptide (Q biogene) and Chariot Kit (Active Motif), GenomONE (ISHIHARA SANGYO KAISHA, LTD.) utilizing HVJ envelope (inactivated hemagglutinating virus of Japan) and the like.
- a cationic lipid such as BioPOTER Protein Delivery Reagent (Gene Therapy Systems), Pro-JectTM Protein Transfection Reagent (PIERCE) and ProVectin (IMGENEX); those based on a lipid, such as Profect-1 (Targeting Systems); those based
- Nuclear reprogramming substance(s) is(are) diluted in an appropriate solvent (e.g., a buffer solution such as PBS or HEPES), a transfer reagent is added, the mixture is incubated at room temperature for about 5 to 15 minutes to form a complex, this complex is added to cells after exchanging the medium with a serum-free medium, and the cells are incubated at 37°C for one to several hours. Thereafter, the medium is removed and replaced with a serum-containing medium.
- an appropriate solvent e.g., a buffer solution such as PBS or HEPES
- Developed PTDs include those using transcellular domains of proteins such as drosophila-derived AntP, HIV-derived TAT ( Frankel, A. et al, Cell 55, 1189-93 (1988 ) or Green, M. & Loewenstein, P. M. Cell 55, 1179-88 (1988 )), Penetratin ( Derossi, D. et al, J. Biol. Chem. 269, 10444-50 (1994 )), Buforin II ( Park, C. B. et al. Proc. Natl Acad. Sci. USA 97, 8245-50 (2000 )), Transportan ( Pooga, M. et al. FASEB J.
- MAP model amphipathic peptide
- K-FGF Lin, Y. Z. et al. J. Biol. Chem. 270, 14255-14258 (1995 )
- Ku70 Sawada, M. et al. Nature Cell Biol. 5, 352-7 (2003 )
- Prion Lundberg, P. et al. Biochem. Biophys. Res. Commun. 299, 85-90 (2002 )
- pVEC Elmquist, A. et al. Exp. Cell Res.
- CPPs derived from the PTDs include polyarginines such as 11R ( Cell Stem Cell, 4,381-384 (2009 )) and 9R ( Cell Stem Cell, 4, 472-476 (2009 )) .
- a fused protein expression vector incorporating cDNA of a nuclear reprogramming substance and PTD or CPP sequence is prepared, and recombination expression is performed using the vector.
- the fused protein is recovered and used for transfer. Transfer can be performed in the same manner as above except that a protein transfer reagent is not added.
- Microinjection a method of placing a protein solution in a glass needle having a tip diameter of about 1 ⁇ m, and injecting the solution into a cell, ensures the transfer of the protein into the cell.
- the protein transferring operation can be performed one or more optionally chosen times (e.g., once or more to 10 times or less, or once or more to 5 times or less and the like).
- the transferring operation can be performed twice or more (e.g., 3 times or 4 times) repeatedly.
- the time interval for repeated transferring operation is, for example, 6 to 48 hours, preferably 12 to 24 hours.
- nuclear reprogramming substance may be used preferably in the form of a nucleic acid that encodes a proteinous factor, rather than the factor as it is.
- the nucleic acid may be a DNA or an RNA, or a DNA/RNA chimera, and may be double-stranded or single-stranded.
- the nucleic acid is a double-stranded DNA, particularly a cDNA.
- a cDNA of a nuclear reprogramming substance is inserted into an appropriate expression vector comprising a promoter capable of functioning in a host somatic cell.
- useful expression vectors include, for example, viral vectors such as retrovirus, lentivirus, adenovirus, adeno-associated virus, herpesvirus and Sendai virus, plasmids for the expression in animal cells (e.g., pAl-11, pXT1, pRc/CMV, pRc/RSV, pcDNAI/Neo) and the like.
- a vector to be used can be chosen as appropriate according to the intended use of the iPS cell to be obtained.
- Useful vectors include adenovirus vector, plasmid vector, adeno-associated virus vector, retroviral vector, lentiviral vector, Sendai virus vector, episomal vector and the like.
- promoters used in expression vectors include the EF1 ⁇ promoter, the CAG promoter, the SR ⁇ promoter, the SV40 promoter, the LTR promoter, the CMV (cytomegalovirus) promoter, the RSV (Rous sarcoma virus) promoter, the MoMuLV (Moloney mouse leukemia virus) LTR, the HSV-TK (herpes simplex virus thymidine kinase) promoter and the like, with preference given to the EF1 ⁇ promoter, the CAG promoter, the MoMuLV LTR, the CMV promoter, the SR ⁇ promoter and the like.
- the expression vector may contain as desired, in addition to a promoter, an enhancer, a polyadenylation signal, a selectable marker gene, a SV40 replication origin and the like.
- selectable marker genes include the dihydrofolate reductase gene, the neomycin resistant gene, the puromycin resistant gene and the like.
- the nucleic acids which are nuclear reprogramming substances may be separately integrated into different expression vectors, or 2 or more, preferably 2 to 3, different genes may be integrated into a single expression vector. Preference is given to the former case with the use of a retroviral or lentiviral vector, which offer high transfection efficiency, and to the latter case with the use of a plasmid, adenovirus, or episomal vector and the like. Furthermore, an expression vector incorporating two or more different genes and another expression vector incorporating one gene alone can be used in combination.
- a plurality of reprogramming genes e.g., 2 or more, preferably 2 or 3 different genes, selected from among Oct3/4, Sox2, Klf4, L-Myc, Lin28 (Lin28b), and SV40LT
- these genes can preferably be integrated into the expression vector via a sequence enabling polycistronic expression.
- a sequence enabling polycistronic expression it is possible to more efficiently express a plurality of genes integrated in one expression vector.
- Useful sequences enabling polycistronic expression include, for example, the 2A sequence of foot-and-mouth disease virus (SEQ ID NO:63; PLoS ONE 3, e2532, 2008 , Stem Cells 25, 1707, 2007 ), the IRES sequence ( U.S. Patent No. 4,937,190 ) and the like, with preference given to the 2A sequence.
- the order of the reprogramming genes is not particularly limited; for example, (i) Sox2 and Klf4, (ii) L-Myc and Lin28 (Lin28b), (iii) Klf4, Sox2 and Oct3/4 can be joined together in this order in the orientation from 5' to 3'.
- An expression vector harboring a reprogramming gene can be introduced into a cell by a technique known per se according to the choice of the vector.
- a viral vector for example, a plasmid containing the nucleic acid is introduced into an appropriate packaging cell (e.g., Plat-E cells) or a complementary cell line (e.g., 293-cells), the viral vector produced in the culture supernatant is recovered, and the vector is infected to a cell by a method suitable for the viral vector.
- an appropriate packaging cell e.g., Plat-E cells
- a complementary cell line e.g., 293-cells
- specific means using a retroviral vector are disclosed in WO2007/69666 , Cell, 126, 663-676 (2006 ) and Cell, 131, 861-872 (2007 ).
- a reprogramming gene is preferably expressed transiently, without being integrated into the chromosome of the cells.
- use of an adenoviral vector whose integration into chromosome is rare, is preferred.
- Specific means using an adenoviral vector is disclosed in Science, 322, 945-949 (2008 ).
- an adeno-associated viral vector is also low in the frequency of integration into chromosome, and is lower than adenoviral vectors in terms of cytotoxicity and inflammation-inducibility, it can be mentioned as another preferred vector.
- Sendai viral vector is capable of being stably present outside the chromosome, and can be degraded and removed using an siRNA as required, it is preferably utilized as well.
- a Sendai viral vector one described in J. Biol. Chem., 282, 27383-27391 (2007 ), Proc. Jpn. Acad., Ser. B 85, 348-362 (2009 ) or JP-B-3602058 can be used.
- a method can be used preferably wherein a nucleic acid encoding a nuclear reprogramming substance is cut out using the Cre-loxP system, when becoming unnecessary. That is, with loxP sequences arranged on both ends of the nucleic acid in advance, iPS cells are induced, thereafter the Cre recombinase is allowed to act on the cells using a plasmid vector or adenoviral vector, and the region sandwiched by the loxP sequences can be cut out.
- the enhancer-promoter sequence of the LTR U3 region possibly upregulates a host gene in the vicinity thereof by insertion mutation, it is more preferable to avoid the expression regulation of the endogenous gene by the LTR outside of the loxP sequence remaining in the genome without being cut out, using a 3'-self-inactivated (SIN) LTR prepared by deleting the sequence, or substituting the sequence with a polyadenylation sequence such as of SV40.
- SIN 3'-self-inactivated
- a plasmid vector can be transferred into a cell using the lipofection method, liposome method, electroporation method, calcium phosphate coprecipitation method, DEAE dextran method, microinjection method, gene gun method and the like.
- lipofection method liposome method
- electroporation method calcium phosphate coprecipitation method
- DEAE dextran method DEAE dextran method
- microinjection method gene gun method and the like.
- Specific means using a plasmid as a vector are described in, for example, Science, 322, 949-953 (2008 ) and the like.
- the transfection can be performed once or more optionally chosen times (e.g., once to 10 times, once to 5 times or the like).
- the transfection can be performed once or more optionally chosen times (e.g., once to 10 times, once to 5 times or the like), preferably the transfection can be repeatedly performed twice or more (e.g., 3 times or 4 times).
- the transgene can get integrated into chromosome; therefore, it is eventually necessary to confirm the absence of insertion of the gene into chromosome by Southern blotting or PCR. For this reason, like the aforementioned Cre-loxP system, it can be advantageous to use a means wherein the transgene is integrated into chromosome, thereafter the gene is removed.
- a method can be used wherein the transgene is integrated into chromosome using a transposon, thereafter a transposase is allowed to act on the cell using a plasmid vector or adenoviral vector so as to completely eliminate the transgene from the chromosome.
- piggyBac a transposon derived from a lepidopterous insect, and the like
- Specific means using the piggyBac transposon is disclosed in Kaji, K. et al., Nature, 458: 771-775 (2009 ), Woltjen et al., Nature, 458: 766-770 (2009 ).
- Another preferable non-integration type vector is an episomal vector, which is capable of self-replication outside the chromosome.
- an episomal vector is disclosed in Yu et al., Science, 324, 797-801 (2009 ).
- episomal vector having loxP sequences placed in the same orientation on the 5' and 3' sides of the vector constituent essential for the replication of the episomal vector can be used. Because an episomal vector is capable of self-replication outside the chromosome, it can ensure stable gene expression in the host cell even if it is not integrated in the genome. It is desirable, however, that the vector be quickly removed once the iPS cell is established.
- the episomal vector it is possible to make the episomal vector to lose its self-replicating potential by flanking a vector constituent essential for the replication of the episomal vector between two loxP sequences, and cutting out the vector constituent by the action of Cre recombinase, whereby the vector can be forced to be early shed from the iPS cell.
- Examples of the episomal vector to be used in the present invention include a vector comprising as a vector component a sequence derived from EBV, SV40 and the like necessary for self-replication.
- the vector component necessary for self-replication is specifically exemplified by a replication origin and a gene that encodes a protein that binds to the replication origin to control the replication; examples include the replication origin oriP and the EBNA-1 gene for EBV, and the replication origin ori and the SV40 large T antigen gene for SV40.
- the episomal expression vector comprises a promoter that controls the transcription of reprogramming genes.
- the promoter used may be as described above.
- the episomal expression vector may further contain as desired an enhancer, a polyadenylation signal, a selection marker gene and the like, as described above. Examples of the selection marker gene include the dihydrofolate reductase gene, the neomycin resistance gene and the like.
- the loxP sequences useful in the present invention include, in addition to the bacteriophage P1-derived wild type loxP sequence (SEQ ID NO:29), optionally chosen mutant loxP sequences capable of deleting the sequence flanked by the loxP sequence by recombination when placed in the same orientation at positions flanking a vector component necessary for the replication of the reprogramming gene.
- mutant loxP sequences include lox71 (SEQ ID NO:30), mutated in 5' repeat, lox66 (SEQ ID NO:31), mutated in 3' repeat, and lox2272 and lox511, mutated in spacer portion.
- the two mutant loxP sequences mutated in spacer portion must be identical (e.g., a pair of lox2272 sequences, a pair of lox511 sequences). Preference is given to a combination of a mutant loxP sequence mutated in 5' repeat (e.g., lox71) and a mutant loxP sequence mutated in 3' repeat (e.g., lox66).
- the loxP sequences remaining on the chromosome have double mutations in the repeats on the 5' side and 3' side as a result of recombination, and are therefore unlikely to be recognized by Cre recombinase, thus reducing the risk of causing a deletion mutation in the chromosome due to unwanted recombination.
- the mutant loxP sequences lox71 and lox66 are used in combination, each may be placed on any of the 5' and 3' sides of the aforementioned vector component, but it is necessary that the mutant loxP sequences be inserted in an orientation such that the mutated sites would be located at the outer ends of the respective loxP sequences.
- a preferred episomal vector of the present invention is a self-removal vector early shedding from the cell even without being acted on by Cre recombinase, there are possibly exceptional cases where longer time is taken for the episomal vector to be shed from the cell. It is preferable, therefore, that the loxP sequences be designed in preparation for risks such as unwanted recombination due to Cre recombinase treatment.
- Each of the two loxP sequences is placed in the same orientation on the 5' and 3' sides of a vector constituent essential for the replication of the reprogramming gene (i.e., a replication origin, or a gene sequence that encodes a protein that binds to the replication origin to control the replication).
- the vector constituent flanked by the loxP sequences may be either the replication origin or a gene sequence that encodes a protein that binds to a replication origin to control the replication, or both.
- the episomal vector or plasmid vector may, for example, have the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) sequence inserted between the reprogramming factor coding region and polyadenylation signal.
- WPRE woodchuck hepatitis virus posttranscriptional regulatory element
- the episomal vector allows the vector to be introduced into the cell using, for example, the lipofection method, liposome method, electroporation method, calcium phosphate coprecipitation method, DEAE dextran method, microinjection method, gene gun method and the like. Specifically, for example, methods described in Science, 324: 797-801 (2009 ) and elsewhere can be used.
- Whether or not the vector component necessary for the replication of the reprogramming gene has been removed from the iPS cell can be confirmed by performing a Southern blot analysis or PCR analysis using a nucleic acid comprising a nucleotide sequence in the vector component and/or in the vicinity of loxP sequence as a probe or primer, with the episome fraction isolated from the iPS cell as a template, and determining the presence or absence of a band or the length of the band detected.
- the episome fraction can be prepared by a method obvious in the art; for example, methods described in Science, 324: 797-801 (2009 ) and elsewhere can be used.
- the episomal vectors containing loxP sequences exhibit not only the essential effect of any episomal vector wherein the exogenous nucleic acid factors (including reprogramming genes) that constitute the vector are not integrated, even transiently, in the genome of the cell, but also the unexpected effect wherein the vector in the form of an episome early shedding from the iPS cell, without being treated with Cre recombinase, when transferred to a somatic cell.
- the present invention also provides an self-removal episomal vector shedding from the cell early after offering a level of the expression of reprogramming factors sufficient to the establishment of an iPS cell.
- This vector is characterized in that it is shed from the iPS cell by the 5th passage at a frequency of 50% or more, preferably 60% or more, more preferably 70% or more.
- the self-removal episomal vector is characterized in that the number of copies per 1x10 4 cells within 1 week after the transfer is on the order of 10 6 cells, whereas the vector is unstable in the cells to the extent that the number of copies per 1x10 4 cells at the time of establishment of iPS cell (e.g., about 4 week after vector transfer) decreases to 100 or less, preferably 50 or less, more preferably 30 or less.
- the early self-removal vector of the present invention has at least one, preferably two or more, more preferably three or more, particularly preferably all, of the following structural features (i) to (iv).
- an inhibitor of p53 in addition to the above-described nuclear reprogramming substances, a functional inhibitor of p53 is brought into contact with the starting cell.
- an inhibitor of p53 function may be any substance capable of inhibiting either (a) the function of the p53 protein or (b) the expression of the p53 gene. That is, not only substances that act directly on the p53 protein to inhibit the function thereof and substances that act directly on the p53 gene to inhibit the expression thereof, but also substances that act on a factor involved in p53 signal transduction to result in inhibition of the function of the p53 protein or the expression of the p53 gene, are also included in the scope of "an inhibitor of p53 function" as mentioned herein.
- the functional inhibitor of p53 is a substance that inhibits the expression of the p53 gene, more preferably an expression vector that encodes an siRNA or shRNA against p53.
- substances that inhibit the function of the p53 protein include, but are not limited to, a chemical inhibitor of p53, a dominant negative mutant of p53 or a nucleic acid that encodes the same, an anti-p53 antagonist antibody or a nucleic acid that encodes the same, a decoy nucleic acid comprising a consensus sequence of a p53-responsive element, a substance that inhibits the p53 pathway, and the like.
- a chemical inhibitor of p53, a dominant negative mutant of p53 or a nucleic acid that encodes the same, and a p53 pathway inhibitor can be mentioned.
- Examples of chemical inhibitors of p53 include, but are not limited to, p53 inhibitors typified by pifithrin (PFT)- ⁇ and - ⁇ , which are disclosed in WO 00/44364 , PFT- ⁇ disclosed in Storm et al. (Nat. Chem. Biol. 2, 474 (2006 )), analogue thereof and salts thereof (for example, acid addition salts such as hydrochlorides and hydrobromides, and the like) and the like.
- PFT pifithrin
- PFT- ⁇ and analogues thereof [2-(2-Imino-4, 5, 6, 7-tetrahydrobenzothiazol-3-yl)-1- p -tolylethanone, HBr (product name: Pifithrin- ⁇ ) and 1-(4-Nitrophenyl)-2-(4,5,6,7-tetrahydro-2-imino-3(2H)-benzothiazolyl)ethanone, HBr (product name: Pifithrin- ⁇ , p-Nitro)], PFT- ⁇ and analogues thereof [2-(4-Methylphenyl)imidazo[2,1-b]-5,6,7,8-tetrahydrobenzothiazole, HBr (product name: Pifithrin- ⁇ , Cyclic) and 2-(4-Nitrophenyl)imidazo[2,1-b]-5,6,7,8-tetrahydrobenzothiazole(product name: Pifith
- Contact of a chemical inhibitor of p53 with a somatic cell can be performed by dissolving the inhibitor at an appropriate concentration in an aqueous or non-aqueous solvent, adding the solution of the inhibitor to a medium suitable for cultivation of somatic cells isolated from a human or mouse (for example, minimal essential medium (MEM), Dulbecco's modified Eagle medium (DMEM), RPMI1640 medium, 199 medium, F12 medium and the like supplemented with about 5 to 20% fetal bovine serum) so that the inhibitor concentration will fall in a range that fully inhibits the p53 function and does not cause cytotoxicity, and culturing the cells for a given period.
- MEM minimal essential medium
- DMEM Dulbecco's modified Eagle medium
- RPMI1640 medium 199 medium, F12 medium and the like supplemented with about 5 to 20% fetal bovine serum
- the inhibitor concentration varies depending on the kind of inhibitor used, and is chosen as appropriate over the range of about 0.1 nM to about 100 nM. Duration of contact is not particularly limited, as far as it is sufficient to achieve nuclear reprogramming of the cells; usually, the inhibitor may be allowed to co-present in the medium until a positive colony emerges.
- the p53 gene is known as a tumor suppressor gene; permanent inhibition of p53 function potentially increases the risk of carcinogenesis.
- Chemical inhibitors of p53 are useful, not only because of the advantage of permitting introduction into cells simply by the addition to the medium, but also because of the ability to terminate the inhibition of p53 function, easily and quickly, by removing the medium containing the inhibitor after induction of iPS cells.
- the choice of dominant negative mutant of p53 is not particularly limited, as far as the mutant is capable of competitively acting against the wild-type p53 protein endogenously expressed in somatic cells to inhibit the function thereof; for example, p53P275S, resulting from point mutation of the proline at the position 275 (in the case of humans, position 278) located in the DNA-binding region of mouse p53 to serine ( de Vries, A., Proc. Natl. Acad. Sci.
- mutants include, for example, p53S58A, resulting from point mutation of the serine at the position 58 of mouse p53 (in the case of humans, position 61) to alanine; p53C135Y, resulting from point mutation of the cysteine at the position 135 of human p53 (in the case of mice, position 132) to tyrosine; p53A135V, resulting from point mutation of the alanine at the position 135 of mouse p53 (in the case of humans, position 138) to valine; p53R172H, resulting from point mutation of the arginine at the position 172 (in the case of humans, position 175) to histidine; p53R270H, resulting from point mutation of the arginine at the position 270 (in the case of humans, position 273) to histidine; p53D278N, resulting from point mutation of the aspartic acid at the position 278 of mouse p53 (in the case of humans, position 28
- a dominant negative mutant of p53 can be obtained by for example, the technique described below.
- an appropriate oligonucleotide is synthesized as a probe or primer on the basis of the mouse or human p53 cDNA sequence information shown by SEQ ID NO:1 or 3, and a mouse or human p53 cDNA is cloned from a mRNA, cDNA or cDNA library derived from a mouse or human cell or tissue, using the hybridization method or the (RT-)PCR method, and is subcloned into an appropriate plasmid.
- a codon of the site into which a mutation is to be introduced (for example, in the case of p53P275S, cct, which is shown by nucleotide numbers 951-953 in the nucleotide sequence shown by SEQ ID NO:1) is replaced with a codon that encodes another desired amino acid (for example, in the case of p53P275S, tct)
- a primer comprising the site is synthesized, and inverse PCR is performed using this primer with the plasmid incorporating the p53 cDNA as a template, whereby a nucleic acid that encodes the desired dominant negative mutant is acquired.
- a primer may be designed outside the site to be deleted, and inverse PCR may be performed as described above.
- the inhibitor of p53 function is a nucleic acid that encodes a dominant negative mutant of p53.
- the nucleic acid may be a DNA or an RNA, or a DNA/RNA chimera, and is preferably a DNA.
- the nucleic acid may be double-stranded or single-stranded.
- a cDNA that encodes a dominant negative mutant of p53 can be cloned by the technique described above with respect to preparation of the mutant protein.
- the cDNA thus isolated like the aforementioned nucleic acids which are nuclear reprogramming substances (reprogramming genes), can be inserted into an appropriate expression vector and transferred to a somatic cell.
- p53 pathway inhibitors include all substances that inhibit any one of the aforementioned signal transduction pathways, but in a preferred mode of embodiment, the p53 pathway inhibitor is a substance that inhibits the expression or function (Myc inhibitory activity) of p21, whose transcription is activated by p53; for example, siRNA, shRNA, antisense nucleic acids, ribozymes against p21 and the like can be mentioned.
- nucleic acids that inhibit the expression of p21 can be designed and synthesized in the same manner as the method for siRNA, shRNA, antisense nucleic acids, and ribozymes against p53 described below, and can be introduced into a somatic cell.
- the nucleic acids may be provided in the form of a vector that expresses them, the vector can be constructed in the same manner as the method for a vector that expresses an siRNA, shRNA, antisense nucleic acid, or ribozyme against p53 described below, and introduced into a somatic cell.
- the p53 pathway inhibitor is a substance that inhibits the ARF-MDM2-p53 pathway; for example, as ARF-MDM2-p53 pathway inhibitors, MDM2, which binds directly to p53 to promote the nuclear export or ubiquitination thereof or a nucleic acid that encodes the same, a substance that inhibits the expression or function of p19 ARF or ATM (ataxia-telangiectasia mutated), which inhibits the action of MDM2 on p53, (for example, siRNAs and shRNAs against these factors) and the like can be mentioned.
- anti-p53 antagonist antibody As examples of other substances that inhibit the function of the p53 protein, anti-p53 antagonist antibody or a nucleic acid that encodes the same can be mentioned.
- the anti-p53 antagonist antibody may be a polyclonal antibody or a monoclonal antibody.
- the isotype of the antibody is not particularly limited, and is preferably IgG, IgM or IgA, particularly preferably IgG.
- the antibody may be, in addition to a complete antibody molecule, for example, a fragment such as Fab, Fab', or F(ab') 2 , a conjugate molecule prepared by a gene engineering technique, such as scFv, scFv-Fc, minibody, or diabody, or a derivative thereof modified with a molecule having protein-stabilizing action, such as polyethylene glycol (PEG).
- An anti-p53 antagonist antibody can be produced using p53 or a partial peptide thereof as an antigen, by a method of antibody or anti-serum production known per se.
- PAb1801 Oncogene Science Ab-2
- DO-1 Oncogene Science Ab-6
- a nucleic acid that encodes an anti-p53 antagonist antibody can be isolated from a hybridoma that produces an anti-p53 monoclonal antibody by a conventional method.
- the H-chain and L-chain genes obtained may be joined together to prepare a nucleic acid that encodes a single-chain antibody.
- an anti-p21 antagonist antibody or a nucleic acid that encodes the same can be mentioned.
- An anti-p21 antagonist antibody and a nucleic acid that encodes the same can also be prepared as with the aforementioned anti-p53 antagonist antibody and nucleic acid that encodes the same.
- Still another substance that inhibits the function of the p53 protein is a decoy nucleic acid comprising a consensus sequence of p53-responsive element (e.g., Pu-Pu-Pu-G-A/T-T/A-C-Py-Py-Py (Pu: purine base, Py: pyrimidine base); SEQ ID NO:27).
- a nucleic acid can be synthesized on the basis of the aforementioned nucleotide sequence information using an automated DNA/RNA synthesizer.
- a decoy nucleic acid is commercially available (e.g., p53 transcription factor decoy (GeneDetect.com)).
- An anti-p53 antagonist antibody and an anti-p21 antagonist antibody, or a nucleic acid that encodes the antibody can be introduced into a cell with the method described in the statement of a dominant negative mutant of p53 or a nucleic acid that encodes the mutant, respectively.
- the aforementioned decoy nucleic acid can be introduced into a cell by lipofection method and the like.
- siRNAs or shRNAs against p53 examples of substances that inhibit the expression of the p53 gene, siRNAs or shRNAs against p53, vectors that express an siRNA or shRNA against p53, antisense nucleic acids against p53 and ribozymes against p53, and the like can be mentioned, and siRNAs and shRNAs against p53 and vectors that express an siRNA or an shRNA are preferable.
- siRNA against p53 can be designed on the basis of the mouse or human p53 cDNA sequence information shown by SEQ ID NO:1 or 3, in accordance with, for example, the rules proposed by Elbashir et al. (Genes Dev., 15, 188-200 (2001 )).
- the target sequence for the siRNA is, as a general rule, AA+(N) 19 , but may be AA+(N) 21 or NA+(N) 21 .
- the 5' end of the sense strand need not to be AA.
- the position of the target sequence is not particularly limited, it is desirable that the target sequence be selected from a region other than 5'-UTR, about 50 bases from the start codon, or 3'-UTR.
- the GC content of the target sequence is also not particularly limited, but the content is preferably about 30 to about 50%; a sequence with no irregularity in GC distribution and with only a few repeats is desirable.
- a polIII promoter is used as a promoter in designing a vector that expresses an siRNA or shRNA of (b2) below, a sequence of 4 or more T or A bases in succession should not be chosen, so as to prevent polymerase transcription from ceasing.
- the target sequence candidates selected on the basis of the above-described rules are examined for homology to sequences of 16-17 bases in succession in mRNAs other than the target, using a homology search software program such as BLAST (http://www.ncbi.nlm.nih.gov/BLAST/), so as to confirm the specificity of the target sequences selected.
- BLAST http://www.ncbi.nlm.nih.gov/BLAST/
- a double-stranded RNA consisting of a sense strand having a 3'-terminal overhang of TT or UU in 19-21 bases after AA (or NA) and an antisense strand having a sequence complementary to the 19-21 bases and a 3'-terminal overhang of TT or UU, is designed as an siRNA.
- an shRNA can be designed by choosing as appropriate an optionally chosen linker sequence capable of forming a loop structure (for example, about 8-25 bases), and ligating the aforementioned sense strand and antis
- siRNAs and/or shRNAs can be searched for using search software programs available at no cost on various websites.
- examples of such sites include, but are not limited to, the siRNA Target Finder (http://www.ambion.com/jp/techlib/misc/siRNA_finder.html) and insert design tool for pSilencer TM Expression Vector (http://www.ambion.com/jp/techlib/misc/psilencer_converter.htm 1), both provided by Ambion, and GeneSeer (http://codex.cshl.edu/scripts/newsearchhairpin.cgi), provided by RNAi Codex; and similar search is possible on the websites of QIAGEN, Takara Bio, SiSearch, Dharmacon, Whitehead Institute, Invitrogen, Promega and the like.
- RNAi Codex Shown below are the sequences of shRNAs against mouse p53 designed using software programs available on the websites of Ambion (SEQ ID NO:5-24) and RNAi Codex (SEQ ID NO:25 and 26).
- the underlined sequences are sense strands (5' side) and antisense strands (3' side) of dsRNAs resulting after cleavage with a dicer (not containing the 3'-overhang "TT"). Small letters indicate a mismatch or a loop.
- An siRNA against p53 can be prepared by synthesizing a sense strand oligonucleotide and antisense strand oligonucleotide designed as described above using an automated DNA/RNA synthesizer separately, and, for example, denaturing the oligonucleotides in an appropriate annealing buffer solution at about 90 to about 95°C for about 1 minute, thereafter annealing the same at about 30 to about 70°C for about 1 to about 8 hours.
- An shRNA against p53 can be prepared by synthesizing oligonucleotides having an shRNA sequence, designed as described above, using an automated DNA/RNA synthesizer, and allowing the same to self-anneal as described above.
- nucleotide molecules that constitute the siRNA and shRNA may be naturally occurring RNAs, the molecules can comprise various chemical modifications in order to increase the stability (chemical and/or against enzyme) or specific activity (affinity for mRNA).
- the phosphoric acid residue (phosphate) of each nucleotide that constitutes the siRNA or shRNA can be substituted with, for example, a chemically modified phosphoric acid residue such as phosphorothioate (PS), methylphosphonate, or phosphorodithionate.
- PS phosphorothioate
- methylphosphonate methylphosphonate
- phosphorodithionate phosphorodithionate
- hydroxyl group at the 2'-position of the sugar (ribose) of each nucleotide may be replaced with -OR (R represents, for example, CH 3 (2'-O-Me), CH 2 CH 2 OCH 3 (2'-O-MOE), CH 2 CH 2 NHC(NH)NH 2 , CH 2 CONHCH 3 , CH 2 CH 2 CN or the like).
- R represents, for example, CH 3 (2'-O-Me), CH 2 CH 2 OCH 3 (2'-O-MOE), CH 2 CH 2 NHC(NH)NH 2 , CH 2 CONHCH 3 , CH 2 CH 2 CN or the like.
- a base moiety pyrimidine, purine
- substitution of the 2-position carbonyl group with thiocarbonyl and the like can be mentioned.
- RNA Ribonucleic acid
- S type C2'-endo
- N type C3'-endo
- S type C2'-endo
- S type C2'-endo
- N type C3'-endo
- BNA LNA
- ENA ENA
- RNA derivatives wherein the conformation of the sugar moiety is fixed at the N type by bridging the 2' oxygen and 4' carbon so as to confer strong bindability to the target RNA, can also be used preferably.
- siRNA against p53 can also be purchased from, for example, Ambion (e.g., Ambion Cat# AM16708, an siRNA ID# 69659, 69753, 69843, 187424, 187425, 187426), Santa Cruz (e.g., Santa Cruz Cat# sc-29436, 44219) and the like.
- Ambion e.g., Ambion Cat# AM16708, an siRNA ID# 69659, 69753, 69843, 187424, 187425, 187426
- Santa Cruz e.g., Santa Cruz Cat# sc-29436, 44219
- siRNA and shRNA against human p53 can also be designed and synthesized using one of the aforementioned search software programs, by inputting the sequence of human p53 cDNA shown by SEQ ID NO:3 or Refseq. No. (NM_000546) and the like as a query, or can also be purchased from Ambion and the like.
- an shRNA against human p53 having the sequence 5'- GACTCCAGTGGTAATCTACTG ctcgagCAGTAGATTACCACTGGAGTC-3' (SEQ ID NO: 28; underlined portion indicates the target sequence for p53; the capital letters indicate the portions where a dsRNA is formed)
- the shRNA against p53 described in Science, 296, 550-553 (2002 ), and the like can be mentioned.
- contact of an siRNA or shRNA against p53 with a somatic cell can be achieved by, as in the case of plasmid DNA, introducing the nucleic acid into the cell using the liposome method, polyamine method, electroporation method, beads method and the like.
- the method using a cationic liposome is the most common and offers high transfer efficiency.
- transfer reagents suitable for introduction of an siRNA such as the GeneEraserTM siRNA transfection reagent (Stratagene), are also commercially available.
- Vectors that express an siRNA are available in the tandem type and the stem loop (hairpin) type.
- the former is the type in which an expression cassette for a sense strand of an siRNA and an expression cassette for an antisense strand are ligated tandem, each strand being expressed in the cell and undergoing annealing to form a double-stranded siRNA (dsRNA).
- dsRNA double-stranded siRNA
- the latter is the type in which an expression cassette for an shRNA is inserted into a vector, the shRNA being expressed in the cell and undergoing processing by a dicer to form a dsRNA.
- a polII promoter for example, immediate-early promoter of CMV
- a polIII promoter in order to allow the accurate transcription of short RNA.
- the polIII promoter mouse and human U6-snRNA promoters, human H1-RNase P RNA promoter, human valine-tRNA promoter and the like can be mentioned.
- a transcription termination signal a sequence of 4 or more T residues in succession is used.
- the siRNA or shRNA expression cassette thus constructed is then inserted into a plasmid vector or a viral vector.
- vectors that can preferably be utilized are the same as those mentioned above in relation to nucleic acids which are nuclear reprogramming substances (reprogramming genes) (viral vectors such as retrovirus, lentivirus, adenovirus, adeno-associated virus, herpesvirus, and Sendai virus; animal cell expression plasmids; episomal vectors and the like).
- a vector, like reprogramming genes can be chosen as appropriate according to the intended use of the iPS cell obtained.
- the p53 gene is known as a cancer suppression gene, and permanent functional inhibition of p53 potentially increases the risk of carcinogenesis.
- the siRNA or shRNA against p53 be designed to be transiently expressed in the cell. For this reason, greater preference is given to plasmid vectors and the like that are incapable of self-replication for use as vectors to harbor a nucleic acid that encodes the siRNA or shRNA against p53.
- the siRNA or shRNA against p53 gives a sufficient iPS cell establishment efficiency even in transient expression from the plasmid.
- a viral vector of retrovirus or the like as an expression vector that encodes the shRNA against p53, a viral vector of retrovirus or the like, a plasmid vector, an episomal vector and the like, prepared on the basis of a commercially available plasmid (for example, pMKO.1-puro p53 shRNA2: #10672, commercially available from Addgene, and the like) or the like can also be used.
- a commercially available plasmid for example, pMKO.1-puro p53 shRNA2: #10672, commercially available from Addgene, and the like
- the aforementioned Cre-loxP system or piggyBac transposon system can also be utilized as required.
- antisense nucleic acids and ribozymes against p53 can be mentioned.
- the antisense nucleic acid may be a DNA or an RNA, or a DNA/RNA chimera.
- the antisense nucleic acid is a DNA
- an RNA:DNA hybrid formed by a target RNA and the antisense DNA is capable of being recognized by endogenous RNase H to cause selective degradation of the target RNA. Therefore, in the case of an antisense DNA that directs the degradation by RNase H, the target sequence may be not only a sequence in p53 mRNA, but also a sequence in the intron region of the primary transcript of the p53 gene.
- the length of the target region for the antisense nucleic acid is not particularly limited, as far as hybridization of the antisense nucleic acid results in an inhibition of the translation into the p53 protein; the target region may be the entire sequence or a partial sequence of p53 mRNA, and may be a sequence of about 15 bases for the shortest, or of the entire sequence of the mRNA or primary transcript for the longest. Considering the ease of synthesis, antigenicity, transferability in cells and other issues, an oligonucleotide consisting of about 15 to about 40 bases, particularly about 18 to about 30 bases, is preferable. Positions of the target sequence include, but are not limited to, 5'- and 3'-UTR, vicinities of the start codon and the like.
- a ribozyme refers to an RNA possessing an enzyme activity to cleave a nucleic acid in the narrow sense, and is herein understood to be used as a concept encompassing a DNA, as far as it possesses sequence-specific nucleic acid cleavage activity.
- One of the most versatile ribozymes is a self-splicing RNA found in infectious RNAs such as viroid and virusoid, and the hammerhead type, the hairpin type and the like are known.
- the hammerhead type exhibits enzyme activity with about 40 bases in length, and it is possible to specifically cleave the target mRNA by making several bases at both ends adjoining to the hammerhead structure portion (about 10 bases in total) be a sequence complementary to the desired cleavage site of the mRNA.
- An antisense nucleic acid or a ribozyme can be synthesized using an automated DNA/RNA synthesizer.
- the nucleotide molecules that constitute them may also have the same modifications as those described above for siRNA, so as to increase the stability, specific activity and the like.
- the antisense nucleic acid or ribozyme can also be used in the form of a nucleic acid that encodes the same, as in the case of siRNA.
- an inhibitor of p53 function needs to be brought into contact with a somatic cell in a way sufficient to inhibit the p53 function in the step of somatic cell nuclear reprogramming.
- the nuclear reprogramming substance and the inhibitor of p53 function may be brought into contact with the somatic cell simultaneously, or either one may be brought into contact in advance.
- the nuclear reprogramming substance is a nucleic acid that encodes a proteinous factor
- the inhibitor of p53 function is a chemical inhibitor
- the former involves a given length of time lag from the transfection treatment to the mass-expression of the proteinous factor
- the latter is capable of rapidly inhibiting the p53 function, so that after the cell is cultured for a given length of time after the transfection treatment, the chemical inhibitor of p53 can be added to the medium.
- the nuclear reprogramming substance and the inhibitor of p53 function are used in the form of viral vectors, plasmid vectors, episomal vectors and the like, both may be simultaneously introduced into the cell.
- iPS cell establishment efficiency improvers include, but are not limited to, histone deacetylase (HDAC) inhibitors [e.g., valproic acid (VPA) ( Nat.
- low-molecular inhibitors such as trichostatin A, sodium butyrate, MC 1293, and M344, nucleic acid-based expression inhibitors such as siRNAs and shRNAs against HDAC (e.g., HDAC1 siRNA Smartpool® (Millipore), HuSH 29mer shRNA Constructs against HDAC1 (OriGene) and the like), and the like], G9a histone methyltransferase inhibitors [e.g., low-molecular inhibitors such as BIX-01294 ( Cell Stem Cell, 2: 525-528 (2008 )), nucleic acid-based expression inhibitors such as siRNAs and shRNAs against G9a (e.g., G9a siRNA (human) (Santa Cruz Biotechnology) and the like) and the like], L-calcium channel agonists (e.g., Bayk8644) ( Cell Stem Cell, 3, 568-574 (2008 )), L-calcium channel agonists (e.g., Bayk86
- nucleic acid-based expression inhibitors may be in the form of expression vectors harboring a DNA that encodes the siRNA or shRNA.
- SV40 large T can also be included in the scope of iPS cell establishment efficiency improvers because they are auxiliary factors unessential for the nuclear reprogramming of somatic cells. While the mechanism of nuclear reprogramming remains unclear, it does not matter whether auxiliary factors, other than the factors essential for nuclear reprogramming, are deemed nuclear reprogramming substances or iPS cell establishment efficiency improvers. Hence, because the somatic cell nuclear reprogramming process is taken as an overall event resulting from contact of nuclear reprogramming substances and an iPS cell establishment efficiency improver with somatic cells, it does not seem always essential for those skilled in the art to distinguish between the two.
- the other iPS cell establishment efficiency improver may be contacted with the somatic cell simultaneously with the nuclear reprogramming substance, and either one may be contacted in advance, as far as the efficiency of iPS cell establishment from a somatic cell improves significantly compared with the efficiency obtained in the absence of the substance; according to the properties of the substance, the substance can be brought into contact with the somatic cell at the same timing as that described above in relation to a functional inhibitor of p53.
- hypoxic conditions means that the ambient oxygen concentration as of the time of cell culture is significantly lower than that in the atmosphere. Specifically, conditions involving lower oxygen concentrations than the ambient oxygen concentrations in the 5-10% CO 2 /95-90% air atmosphere, which is commonly used for ordinary cell culture, can be mentioned; examples include conditions involving an ambient oxygen concentration of 18% or less.
- the ambient oxygen concentration is 15% or less (e.g., 14% or less, 13% or less, 12% or less, 11% or less and the like), 10% or less (e.g., 9% or less, 8% or less, 7% or less, 6% or less and the like), or 5% or less (e.g., 4% or less, 3% or less, 2% or less and the like).
- the ambient oxygen concentration is preferably 0.1% or more (e.g., 0.2% or more, 0.3% or more, 0.4% or more and the like), 0.5% or more (e.g., 0.6% or more, 0.7% or more, 0.8% or more, 0.95% or more and the like), or 1% or more (e.g., 1.1% or more, 1.2% or more, 1.3% or more, 1.4% or more and the like).
- CO 2 incubators permitting adjustment of oxygen concentration are commercially available from various manufacturers (e.g., CO 2 incubators for hypoxic culture manufactured by Thermo scientific, Ikemoto Scientific Technology, Juji Field, Wakenyaku etc.).
- the time of starting cell culture under hypoxic conditions is not particularly limited, as far as iPS cell establishment efficiency is not prevented from being improved compared with the normal oxygen concentration (20%).
- the culture may be started before the somatic cell is contacted with the nuclear reprogramming substance, or at the same time as the contact, or after the contact, it is preferable, for example, that the culture under hypoxic conditions be started just after the somatic cell is contacted with the nuclear reprogramming substance, or at a given time interval after the contact [e.g., 1 to 10 (e.g., 2, 3, 4, 5, 6, 7, 8 or 9) days].
- the duration of cultivation of cells under hypoxic conditions is not particularly limited, as far as iPS cell establishment efficiency is not prevented from being improved compared with the normal oxygen concentration (20%); examples include, but are not limited to, periods of 3 days or more, 5 days or more, for 7 days or more or 10 days or more, and 50 days or less, 40 days or less, 35 days or less or 30 days or less and the like.
- Preferred duration of cultivation under hypoxic conditions varies depending on ambient oxygen concentration; those skilled in the art can adjust as appropriate the duration of cultivation according to the oxygen concentration used.
- a normal oxygen concentration be restored from hypoxic conditions before starting drug selection.
- preferred starting time and preferred duration of cultivation for cell culture under hypoxic conditions also vary depending on the choice of nuclear reprogramming substance used, iPS cell establishment efficiency at normal oxygen concentrations and the like.
- the cell After being contacted with nuclear reprogramming substances and a functional inhibitor of p53 (and another iPS cell establishment efficiency improver if required), the cell can, for example, be cultured under conditions suitable for culturing ES cells.
- the culture In the case of mouse cells, the culture is carried out with the addition of Leukemia Inhibitory Factor (LIF) as a differentiation suppression factor to an ordinary medium.
- LIF Leukemia Inhibitory Factor
- bFGF basic fibroblast growth factor
- SCF stem cell factor
- the cell is cultured in the co-presence of mouse embryonic fibroblasts treated with radiation or an antibiotic to terminate the cell division, as feeder cells.
- Mouse embryonic fibroblasts in common use as feeders include the STO cell line (ATCC CRL-1503) and the like; for induction of an iPS cell, the SNL cell generated by stably integrating the neomycin resistance gene and the LIF gene in the STO cell (SNL76/7 STO cell; ECACC 07032801) [ McMahon, A. P. & Bradley, A. Cell 62, 1073-1085 (1990 )] and the like are commonly used.
- SNL76/7 STO cell SNL76/7 STO cell; ECACC 07032801
- McMahon, A. P. & Bradley, A. Cell 62, 1073-1085 (1990 ) and the like are commonly used.
- MEF mouse embryonic primary fibroblast
- Mitomycin C-treated MEFs are commercially available from Millipore and ReproCELL. Co-culture with these feeder cells may be started before contact of the nuclear reprogramming substance, at the time of the contact, or after the contact (for
- the present inventors succeeded in providing for the first time a method of generating a human iPS cell using nuclear reprogramming substances of the present invention and a functional inhibitor of p53 in combination with a non-viral vector, preferably an episomal vector, especially of the early self-removal type, wherein no ingredient from a non-human animal is used (i.e., under completely xeno-free conditions) in the cultivation from the transfer of the nuclear reprogramming substances and functional inhibitor of p53 to the somatic cell to the establishment and maintenance of an iPS cell.
- a non-viral vector preferably an episomal vector, especially of the early self-removal type, wherein no ingredient from a non-human animal is used (i.e., under completely xeno-free conditions) in the cultivation from the transfer of the nuclear reprogramming substances and functional inhibitor of p53 to the somatic cell to the establishment and maintenance of an iPS cell.
- the starting cell is cultured in a medium free of FCS and other ingredients from non-human animals after being brought into contact with nuclear reprogramming substances and a functional inhibitor of p53 (and another iPS cell establishment efficiency improver if required).
- Useful substances to be added as differentiation suppression factors to the medium are in the form of a purified human protein, preferably a recombinant protein.
- Optionally chosen human somatic cells can be used as feeder cells; examples of preferred feeder cells include human dermal fibroblasts (HDFs), human dental pulp stem cells and the like. It is also possible to induce a human iPS cell without using feeder cells.
- a commercially available xeno-free coating agent may be used to coat the cell container in place of Matrigel and gelatin.
- a candidate colony of iPS cells can be selected by a method with drug resistance and reporter activity as indicators, and also by a method based on macroscopic examination of morphology.
- a colony positive for drug resistance and/or reporter activity is selected using a recombinant cell wherein a drug resistance gene and/or a reporter gene is targeted to the locus of a gene highly expressed specifically in pluripotent cells (for example, Fbx15, Nanog, Oct3/4 and the like, preferably Nanog or Oct3/4).
- a mouse-derived MEF wherein the ⁇ geo (which encodes a fusion protein of ⁇ -galactosidase and neomycin phosphotransferase) gene is knocked-in to the Fbx15 gene locus ( Takahashi & Yamanaka, Cell, 126, 663-676 (2006 )), or a transgenic mouse-derived MEF wherein green fluorescent protein (GFP) gene and the puromycin resistance gene are integrated in the Nanog gene locus ( Okita et al., Nature, 448, 313-317 (2007 )) and the like can be mentioned.
- GFP green fluorescent protein
- methods for selecting a candidate colony by macroscopic examination of morphology include, for example, the method described by Takahashi et al. in Cell, 131, 861-872 (2007 ). Although methods using reporter cells are convenient and efficient, colony selection by macroscopic examination is desirable from the viewpoint of safety when iPS cells are prepared for the purpose of human treatment.
- the identity of the cells of the selected colony as iPS cells can be confirmed by positive responses to Nanog (or Oct3/4) reporters (puromycin resistance, GFP positivity and the like), as well as by the formation of a visible ES cell-like colony, as described above; however, to increase the accuracy, it is possible to perform tests such as alkaline phosphatase staining, analyzing the expression of various ES-cell-specific genes, and transplanting the cells selected to a mouse and confirming teratoma formation.
- the iPS cells thus established can be used for various purposes. For example, by utilizing a method of differentiation induction reported with respect to ES cells, differentiation into various cells (e.g., myocardial cells, blood cells, nerve cells, vascular endothelial cells, insulin-secreting cells and the like) from iPS cells can be induced. Therefore, inducing iPS cells using a somatic cell collected from a patient or another person of the same or substantially the same HLA type would enable stem cell therapy by autogeneic or allogeneic transplantation, wherein the iPS cells are differentiated into desired cells (that is, cells of an affected organ of the patient, cells that have a therapeutic effect on disease, and the like), which are transplanted to the patient.
- desired cells that is, cells of an affected organ of the patient, cells that have a therapeutic effect on disease, and the like
- Retroviruses for reprogramming were prepared on the basis of the pMXs plasmid and Plat-E packaging cells [supplied by Dr. Toshio Kitamura at the University of Tokyo; Morita, S. et al., Gene Ther. 7, 1063-1066 (2000 )].
- Various constructs were inserted into the multicloning site of pMXs to yield retroviral vectors to be used for reprogramming.
- the constructs inserted were prepared by joining human Oct3/4 (O in Fig. 1 ), human Sox2 (S in Fig. 1 ), human Klf4 (K in Fig. 1 ), human c-Myc (M in Fig. 1 ), human Lin28 (L in Fig.
- Each retrovirus for reprogramming was prepared by transferring each of the aforementioned retroviral vectors to Plat-E cells that had been seeded to a 6-well culture plate (Falcon) at 0.6x10 6 cells per well on the day before.
- the cells were cultured at 37°C in the presence of 5% CO 2 using DMEM/10% FCS [a culture broth prepared by adding 10% fetal calf serum to DMEM (Nacalai Tesque)].
- DMEM/10% FCS a culture broth prepared by adding 10% fetal calf serum to DMEM (Nacalai Tesque)].
- FuGene6 transfection reagent (Roche) was placed in 100 ⁇ L of Opti-MEM I Reduced-Serum Medium (Invitrogen), and the cells were allowed to stand at room temperature for 5 minutes.
- each expression vector was added, and the cells were allowed to further stand at room temperature for 15 minutes, after which they were added to the Plat-E culture broth.
- the Plat-E supernatant was replaced with a fresh supply of the medium.
- the culture supernatant was recovered and filtered through a 0.45 ⁇ m sterile filter (Whatman), and polybrene (Nacalai) was added at 4 ⁇ g/mL to yield a viral liquid.
- a fibroblast established from a skin from a neonatal Caucasian was used after being transfected with mouse Slc7a1 by means of lentivirus.
- This fibroblast was cultured and maintained at 37°C in the presence of 5% CO 2 in a 100 mm culture dish using DMEM/10% FCS as a culture broth.
- the medium was removed, and the cells were washed by the addition of 5 mL of PBS.
- 0.25% Trypsin/1 mM EDTA (Invitrogen) was added, and a reaction was carried out at 37°C for about 5 minutes.
- DMEM/10% FCS was added to suspend the cells, and 1.3x10 5 cells were seeded to one well of a 6-well culture plate (Falcon).
- the cells were mixed and infected with each retrovirus that had been produced using Plat-E cells. 24 hours later, the medium was replaced with a fresh supply to terminate the infection. On day 6 after the start of the infection, the medium was removed from the plate, and the cells were washed by the addition of 1 mL of PBS. After removing the PBS, 0.25% Trypsin/1 mM EDTA (Invitrogen) was added, and a reaction was carried out at 37°C for about 5 minutes. After the cells rose, DMEM/10% FCS was added to suspend the cells, and 5x10 5 cells were seeded to a 100 mm dish containing previously seeded feeder cells.
- Trypsin/1 mM EDTA Invitrogen
- the feeder cells used were SNL cells that had been treated with mitomycin C to terminate cell division.
- the medium was replaced with a primate ES cell culture medium (ReproCELL) supplemented with 4 ng/mL bFGF (Wako); this medium exchange was continued every 2 days.
- ReproCELL primate ES cell culture medium
- bFGF bFGF
- Fig. 1 Photographs of colonies and colony counts are shown in Fig. 1 .
- the results of colony counting are summarized in Fig. 2 .
- the establishment efficiency for human iPS colonies was much higher with the use of L-Myc in place of c-Myc.
- a plasmid for reprogramming was prepared on the basis of pCX-EGFP (supplied by Dr. Masaru Okabe at Osaka University; FEBS Letters, 407, 313-319, 1997 ).
- WPRE woodchuck hepatitis virus posttranscriptional regulatory element
- a cassette for replicating this vector in the cell was prepared by inserting a loxP sequence into both ends of the EBNA-1 of pCEP4 (Invitrogen). This cassette containing the EBNA-1 and oriP was integrated into the BamHI site of the aforementioned pCX-EGFP incorporating the WPRE, and this was named pCXLE-EGFP.
- This pCXLE-EGFP was treated with EcoRI, and various constructs, in place of EGFP, were inserted to yield plasmids for reprogramming.
- the five constructs inserted were: 1) human Oct3/4, 2) a construct prepared by joining the translated regions of human Sox2 and human Klf4 via the 2A sequence of foot-and-mouth disease virus, 3) a construct prepared by joining the translated regions of human Klf4, human Sox2 and human Oct3/4 via the 2A sequence of foot-and-mouth disease virus, 4) a construct prepared by joining the translated regions of human c-Myc, human Lin28 and Nanog via the 2A sequence of foot-and-mouth disease virus, and 5) SV40 Large T antigen (each construct is under the control of the CAG promoter and rabbit ⁇ -globin polyA sequence), which were designated as pCXLE-hOct4, pCXLE-hSK, pCXLE-hKSO, pCXLE-hMLN, and p
- a fibroblast established from a facial skin from a 36-year-old Caucasian female (Cell Applications, Lot1388) was used. This fibroblast was cultured and maintained at 37°C in the presence of 5% CO 2 in a 100 mm culture dish using DMEM/10% FCS [a culture broth prepared by adding 10% fetal bovine serum to DMEM (Nacalai Tesque)]. At the time of plasmid transfer, the medium was removed, and the cells were washed by the addition of 5 mL of PBS. After removing the PBS, 0.25% Trypsin/1 mM EDTA (Invitrogen) was added, and a reaction was carried out at 37°C for about 5 minutes.
- DMEM/10% FCS was added to suspend the cells, and 6x10 5 cells were recovered in a 15 mL centrifugal tube. The suspension was centrifuged at 800 rpm for 5 minutes, and the supernatant was removed. A total of 3 ⁇ g of plasmids (0.5 ⁇ g pCXLE-hOct4, 1 ⁇ g pCXLE-hSK, 0.5 ⁇ g pCXLE-hKSO, 0.5 ⁇ g pCXLE-hMLN, 0.5 ⁇ g pCX-SV40LT) was transferred to the cells using Microporator (AR BROWN).
- DMEM/10% FCS was added to suspend the cells, and 2x10 5 cells were seeded to a 100 mm dish containing previously seeded feeder cells.
- the feeder cells used were mitomycin C-treated MEF.
- the medium was replaced with a primate ES cell culture medium (ReproCELL) supplemented with 4 ng/mL bFGF (Wako); this medium exchange was continued every 2 days.
- ReproCELL a primate ES cell culture medium
- bFGF Wi-Fi
- plasmids other than pCX-SV40LT, which was used in Example 2, were used for reprogramming: pCXLE-hOct4, pCXLE-hSK, pCXLE-hKSO, and pCXLE-hMLN.
- a fibroblast established from a facial skin from a 36-year-old Caucasian female (Cell Applications, Lot1388) was used. This fibroblast was cultured and maintained at 37°C in the presence of 5% CO 2 in a 100 mm culture dish using DMEM/10% FCS [a culture broth prepared by adding 10% fetal bovine serum to DMEM (Nacalai Tesque)]. At the time of plasmid transfer, the medium was removed, and the cells were washed by the addition of 5 mL of PBS. After removing the PBS, 0.25% Trypsin/1 mM EDTA (Invitrogen) was added, and a reaction was carried out at 37°C for about 5 minutes.
- DMEM/10% FCS was added to suspend the cells, and 6x10 5 cells were recovered in a 15 mL centrifugal tube. The suspension was centrifuged at 800 rpm for 5 minutes, and the supernatant was removed. A total of 3 ⁇ g of plasmids (1 ⁇ g pCXLE-hOct4, 1 ⁇ g pCXLE-hSK, 0.5 ⁇ g pCXLE-hKSO, 0.5 ⁇ g pCXLE-hMLN) was transferred to the cells using Microporator (AR BROWN). This transfer took place using a 100 ⁇ L chip with three pulses at 1650 V for 10 ms.
- the transfected cells were transferred to a 6-well culture plate (Falcon) containing 3 mL of DMEM/10% FCS, and cultured at 37°C in the presence of 5% CO 2 for 6 days. Subsequently, the medium was removed, and the cells were washed by the addition of 2 mL of PBS. After removing the PBS, 0.25% Trypsin/1 mM EDTA (Invitrogen) was added, and a reaction was carried out at 37°C for about 5 minutes. After the cells rose, DMEM/10% FCS was added to suspend the cells, and 1x10 5 cells were seeded to a 100 mm dish containing previously seeded feeder cells.
- the feeder cells used were mitomycin C-treated MEF or SNL76/7.
- the medium was replaced with a primate ES cell culture medium (ReproCELL) supplemented with 4 ng/mL bFGF (Wako); this medium exchange was continued every 2 days.
- ReproCELL primate ES cell culture medium
- bFGF bFGF
- a DNA that encodes a shRNA against human p53 [5'- GACTCCAGTGGTAATCTAC ttcaagagaGTAGATTACCACTGGAGTC-3' (SEQ ID NO:32): the underlined portion is the target sequence for p53; the capitalized letters indicate the portion where dsRNA is formed; hereinafter simply referred to as p53 shRNA] was also used.
- pCXLE-hOct4 In addition to pCXLE-hOct4, pCXLE-hSK, and pCXLE-hMLN as prepared in Example 2, 1) a plasmid prepared by treating pCXLE-EGFP as prepared in Example 2 with EcoRI, and incorporating a construct prepared by joining the translated regions of human L-Myc and human Lin28 via the 2A sequence of foot-and-mouth disease virus, in place of EGFP (pCXLE-hUL) and 2) a plasmid incorporating a construct expressing an shRNA against p53 (driven by the U6 promoter) inserted in the BamHI site of pCXLE-hOct4 (pCXLE-hOct4-shp53) were prepared and used.
- pCXLE-EGFP was used as a control.
- the structures of pCXLE-hOct4-shp53, pCXLE-hSK and pCXLE-hUL are shown in Fig.30 (in this figure, pCXLE-hOct4-shp53 is described as pCXLE-hOct3/4-shp53).
- a fibroblast established from a skin from a 21-year-old Japanese woman (JCRB, TIG113) was used after being transfected with mouse Slc7a1 by means of lentivirus.
- This fibroblast was cultured and maintained at 37°C in the presence of 5% CO 2 in a 100 mm culture dish using DMEM/10% FCS [a culture broth prepared by adding 10% fetal bovine serum to DMEM (Nacalai Tesque)].
- DMEM/10% FCS a culture broth prepared by adding 10% fetal bovine serum to DMEM (Nacalai Tesque)].
- the medium was removed, and the cells were washed by the addition of 5 mL of PBS.
- the transfected cells were transferred to a 6-well culture plate (Falcon) containing 3 mL of DMEM/10% FCS, and cultured at 37°C in the presence of 5% CO 2 for 7 days. Subsequently, the medium was removed, and the cells were washed by the addition of 2 mL of PBS. After removing the PBS, 0.25% Trypsin/1 mM EDTA (Invitrogen) was added, and a reaction was carried out at 37°C for about 5 minutes. After the cells rose, DMEM/10% FCS was added to suspend the cells, and 1.5x10 5 cells were seeded to a 100 mm dish containing previously seeded feeder cells.
- the feeder cells used were mitomycin C-treated MEF or SNL76/7.
- the medium was replaced with a primate ES cell culture medium (ReproCELL) supplemented with 4 ng/mL bFGF (Wako); this medium exchange was continued every 2 days.
- the human ES cell-like colonies that had emerged were counted. Photographs of the colonies are shown in Fig. 5 . Results of colony counting are shown in Table 2 and Fig. 6 (MEF used as feeder). Table 2 Exp. No.
- Vector contents ( ⁇ g) (Microporator conditions: 1650V, 10ms, x3) MEF feeder MSTO feeder pCXLE-hOct4 pCXLE-hOct4-shp53 pCXLE-hSK pCXLE-hMLN pCXLE-hUL pCXLE-EGFP non-ES like ES like non-ES like ES like 375A 1 1 1 1 0 1 0 0 375B, D 1 1 1 10 13 3 6 375C, E 1 1 1 71 136 87 132 control 3 0 0 0 0 375A-C: MEF feeder; 375D-E: MSTO feeder
- iPS colonies (ES-like colonies) could be established whichever feeders were used, more colonies were established with the use of MEF.
- 5 genes consisting of Oct3/4, Sox2, Klf4, L-Myc, and Lin28 were used, the establishment efficiency increased compared with the use of the conventional 6 genes (Oct3/4, Sox2, Klf4, c-Myc, Lin28 and Nanog).
- the p53 shRNA was further added, the establishment efficiency increased dramatically.
- the plasmids used for reprogramming were the same as the five different plasmids pCXLE-hOct4, pCXLE-hSK, pCXLE-hMLN, pCXLE-hUL, and pCXLE-hOct4-shp53 in Example 4; pCXLE-EGFP was used as a control.
- a fibroblast established from a skin from a 6-year-old Japanese female (JCRB, TIG120) and a fibroblast established from a skin from an 8-month-old Japanese male (JCRB, TIG121) were used after being transfected with mouse Slc7a1 by means of lentivirus.
- These fibroblasts were cultured and maintained at 37°C in the presence of 5% CO 2 in a 100 mm culture dish using DMEM/10% FCS [a culture broth prepared by adding 10% fetal bovine serum to DMEM (Nacalai Tesque)].
- DMEM/10% FCS a culture broth prepared by adding 10% fetal bovine serum to DMEM (Nacalai Tesque)].
- the medium was removed, and the cells were washed by the addition of 5 mL of PBS.
- the transfected cells were transferred to a 6-well culture plate (Falcon) containing 3 mL of DMEM/10% FCS, and cultured at 37°C in the presence of 5% CO 2 for 7 days. Subsequently, the medium was removed, and the cells were washed by the addition of 2 mL of PBS. After removing the PBS, 0.25% Trypsin/1 mM EDTA (Invitrogen) was added, and a reaction was carried out at 37°C for about 5 minutes. After the cells rose, DMEM/10% FCS was added to suspend the cells, and 1x10 5 cells were seeded to a 100 mm dish containing previously seeded feeder cells.
- the feeder cells used were mitomycin C-treated MEF or SNL76/7.
- the medium was replaced with a primate ES cell culture medium (ReproCELL) supplemented with 4 ng/mL bFGF (Wako); this medium exchange was continued every 2 days.
- the human ES cell-like colonies that had emerged were counted. Photographs of the colonies are shown in Fig. 7 (TIG120 used) and Fig. 8 (TIG121 used). Results of colony counting are shown in Table 3, Fig. 9 (TIG120 used, MEF used as feeder) and Fig. 10 (TIG121 used, MEF used as feeder).
- HDF source Vector contents ( ⁇ g) (Microporator conditions: 1650V, 10ms, x3) MEF feeder MSTO feeder pCXLE-hOct4 pCXLE-shp53 pCXLE-hSK pCXLE-hMLN pCXLE-hUL pCXLE-EGFP non-ES like ES like non-ES like ES like 380A TIG120 1 1 1 1 3 0 0 380B TIG120 1 1 7 11 1 2 380C TIG120 1 1 1 1 4 16 0 4 380D TIG120 1 1 1 37 71 17 25 Control TIG120 3 0 0 0 0 380E TIG121 1 1 1 2 3 0 0 380F TIG121 1 1 1 1 11 10 1 4 380G TIG121 1 1 1 1 9 23 0 0 380H TIG121 1 1 1 24 97 5 11 Control TIG121 3 0 0 0 0 0 0 0
- iPS cells After becoming nearly confluent in a 6-well culture plate (Falcon), the iPS cells were washed by the addition of 2 mL of PBS. After removing the PBS, 400 ⁇ L of a genome recovery buffer (50 mM Tris-HCl, 20 mM EDTA, 100 mM NaCl, 1% SDS, 50 ⁇ g/mL proteinase K) was added to lyse the cells, and the cells were recovered in a 1.5 mL tube, after which the cell lysate was incubated at 55°C overnight.
- a genome recovery buffer 50 mM Tris-HCl, 20 mM EDTA, 100 mM NaCl, 1% SDS, 50 ⁇ g/mL proteinase K
- PCR was also performed on controls prepared by adding 200, 20, or 2 fg of the plasmid that had been transferred to the genome (50 ng) of the starting fibroblast ("+plasmid" in Fig. 12 ). The results are shown in Fig. 12 .
- any of the iPS cells examined none of Klf4 and c-Myc from the exogenous gene (Tg) and the vector constituent OriP was detected in the long DNA (L in Fig. 12 ) or the short DNA (S in Fig. 12 ); it was estimated that the episomal plasmid transferred had spontaneously been shed the cell.
- Fibroblasts established from skins from male and female Japanese and Caucasian subjects at various ages (HDF) as sources of somatic cells were transfected with 5 genes consisting of Oct3/4, Sox2, Klf4, L-Myc, and Lin28, along with p53 shRNA, using pCXLE-hOct4-shp53, pCXLE-hSK and pCXLE-hUL in the same manner as Example 5.
- MSTO or MEF served as feeder cells.
- colony counts are shown as mean numbers of colonies established per 1x10 5 HDFs. As is evident from Table 4, it was found that iPS cells could be established irrespective of the age, sex, and race of the cell source subject. It was also found that iPS cells could be established whether Slc7a1 was transferred (no separate data shown).
- the p53 gene is known as a cancer suppression gene; functional inhibition of p53 for a long time potentially increases the risk of carcinogenesis.
- an investigation was made to determine whether iPS cells could be established as with an episomal vector even when p53 shRNA was expressed by means of a transient expression vector (an ordinary plasmid vector lacking the EBNA-1 and oriP: hereinafter, the plasmid vector).
- iPS cell was established in the same manner as Example 5 using a fibroblast established from a skin from a 36-year-old Caucasian female (HDF1388) as a somatic cell, with MEF as feeder cells. The transfer took place using Microporator and a 100 ⁇ L chip with three pulses at 1650 V for 10 ms. On day 27 after the transfer, the human ES cell-like colonies that had emerged were counted. The results are shown in Fig. 14 . Comparing the combinations (a) and (b) (Epi versus Trans of +M-L-N in Fig. 14 ), and the combinations (c) and (d) (Epi versus Trans of +U-L in Fig.
- HLA-A, HLA-B, HLA-Cw and HLA-DRB1 were supplied by Drs. Takahiro Kunisada and Kenichi Tezuka at Gifu University. These cell lines had been established as described in J. Dent. Res., 87 (7): 676-681 (2008 ) and WO 2010/013359 .
- the aforementioned four HLA genotypes of the two cell lines and the allelic frequency thereof [frequency of each allele (haplotype) having the four HLA genotypes in all alleles in Japanese people] are shown in Table 5.
- Table 5 HLA allele population A B Cw DRB1 DP74 2402 5201 1202 1502 10% DP94 1101 1501 0401 0406 1.5%
- iPS cells were established in the same manner as Example 5 using five different plasmids for reprogramming: pCXLE-hOct4, pCXLE-hSK, pCXLE-hMLN, pCXLE-hUL and pCXLE-hOct4-shp53. iPS cells were also established by transferring the plasmid described in Science, 324: 797-801 (2009 ) (Thomson's mix). A total of 3 ⁇ g of vector was used in each case; this transfer took place using Microporator and a 100 ⁇ L chip with three pulses at 1650 V for 10 ms. MSTO was used as feeder cells.
- Photographs of iPS cells established by transferring pCXLE-hOct4-shp53, pCXLE-hSK and pCXLE-hUL to DP74 and DP94 are shown in Fig. 15 .
- the human ES cell-like colonies that emerged on day 28 after the transfer were counted.
- the results are shown in Figs. 16 and 17 (each numerical figure indicates the mean and standard deviation for three experiments).
- DP74 line Fig. 16
- DP94 line Fig.
- pCXLE-EGFP was transferred to HDF, and an investigation was made to determine how the expression of EGFP disappeared. Every week from the 1st to 4th week after the transfer, the amount expressed (fluorescence intensity) of EGFP in 1x10 4 cells was analyzed by FACS. The results are shown in Fig. 18 . The amount expressed of EGFP and the number of cells showing the expression decreased over weeks; 4 weeks after the transfection, GFP-positive cells had decreased to as low as 2.4%.
- a 0.2 mL tube containing 5 ⁇ L of a genome recovery buffer (the buffer for TaKaRa Ex Taq supplemented with 167 ⁇ g/mL proteinase K) was provided.
- a genome recovery buffer the buffer for TaKaRa Ex Taq supplemented with 167 ⁇ g/mL proteinase K
- the tube was incubated at 55°C for 3 hours to obtain a cell lysate.
- the lysate was heated at 95°C for 3 minutes to inactivate the proteinase K. This was used as it was as a template for real-time PCR.
- the PCR was performed using SYBR Premix EX Taq II (Takara Shuzo).
- DP-derived epi-iPS cells The results of DP-derived epi-iPS cells are shown in Fig. 31A .
- the later clone is likely to have integration of the plasmid into a chromosome.
- fibroblast-derived epi-iPS cells are shown in Fig. 31B .
- clones including 404C-2 and 409B-2, we were unable to detect any episomal vectors. These data demonstrated that in the majority of epi-iPSC clones, the episomal vectors were spontaneously lost.
- RNA was extracted from the iPS cells in one well of a 6-well plate; 1 ⁇ g thereof, the primer dT (20) and the reverse transcriptase Rever Tra Ace (TOYOBO) were used to reverse-transcribe the mRNA to a complementary strand DNA.
- the final volume of the reaction product was 20 ⁇ L.
- Added to this reverse transcript was 60 ⁇ L of H 2 O.
- Quantitative PCR was performed for each transgene with 1 ⁇ L of the reaction product (equivalent to 12.5 ng of RNA) as a template, and with SYBR Green II as an indicator, using the primer sets shown in Table 6 below, one for measuring the sum of the amount of exogenous genes expressed and the amount of endogenous genes expressed (total amount expressed), and the other for measuring the amount of exogenous genes expressed.
- the PCR amplification conditions used were as follows: 1 cycle at 95°C for 30 seconds, followed by 50 cycles at 94°C for 10 seconds, 60°C for 10 seconds, and 72°C for 30 seconds.
- each of pCXLE-hOct4-shp53, pCXLE-hSK and pCXLE-hUL, which had been used for the transfection was prepared as a 10 6 copies/ ⁇ L solution, and this solution was serially diluted 10-fold.
- quantitative PCR was performed in the same manner.
- a standard curve was generated for each of the primer set for measuring the total amount expressed and the primer set for measuring the amount of exogenous genes expressed.
- the results of quantitative PCR for each iPS cell were converted using this standard curve, and the number of copies of each gene per 12.5 ng of total RNA was calculated as the total amount expressed and the amount of exogenous genes expressed.
- Results of a clustering analysis based on differences in the amount expressed among various genes are shown in Fig. 22 .
- Results of scatter plot analysis are shown in Fig. 23 .
- the iPS cells established using an episomal vector exhibited an expression pattern similar to that of ES cells, and were therefore proven to be iPS cells similar to ES cells.
- Results of CGH array analysis are shown in Fig. 24 .
- a comparison with the TIG cell used for the transfer showed no major abnormalities.
- a karyotype analysis by G band staining on some cells revealed no abnormal findings.
- the DNA methylation levels of CpG sites in the promoter region of NANOG were high in parental HDF and DP cells, but were low in epi-iPS and ES cells ( Fig. 33 ).
- Fig. 34 Histological exmaination confirmed that these tumors were teratomas and contained tissues of all three germ layers, including neural epithelium, cartilage, muscle, and gut-like epithelium ( Fig. 34 A , B ).
- differentiation medium was prepared as follows: DMEM/F12 supplemented with 5% Knockout Serum Replacement (KSR; Invitrogen), 2 mM glutamine, 0.1 mM nonessential amino acids, and 0.1 mM 2-mercaptoethanol.
- KSR Knockout Serum Replacement
- iPS cells were dissociated into single cells in Accumax (Invitrogen) and quickly re-aggregated in the differentiation medium supplemented with 10 ⁇ M Y-27632, 2 ⁇ M dorsomorphin, and 10 ⁇ m SB431542 (Sigma) at a density of 9000 cells/150 ⁇ l/well using 96-well low cell-adhesion plates (LIPIDURE-COAT PLATE A-U96, NOF Corporation). After 5 days of cultivation, cell aggregates were stimulated with 100 ng/ml FGF-8 and 20 ng/ml Wnt1. From day 8, 200 ng/ml SHH was present to the medium.
- the aggregated cells were collected and transferred to a 60 mm poly-ornithine/laminin-coated dish in NB medium (Neurobasal medium containing B27 supplement; Invitrogen) with 200 ng/ml SHH. Thereafter, the medium was changed to NB medium supplemented with 1 ng/ml FGF-20 and 12.5 ng/ml bFGF on day 15.
- the cells were harvested on day 22 and seeded onto 8-well chamber plates at a density of 2 ⁇ 10 5 per well in NB medium supplemented with 2 ng/ml GDNF, 20 ng/ml BDNF, 400 ⁇ M dbcAMP, and 200 ⁇ M ascorbic acid.
- Fig. 35 The results are shown in Fig. 35 .
- TH-positive cells also colocalized with the neural markers Tuj1 and MAP2ab, and the dopamine transporter VMAT2 ( Fig.
- epi-iPSCs have the potential to differentiate into dopaminergic neurons.
- the epi-iPSCs established by the use of the Y3 mixture (pCXLE-hOct4, pCXLE-hSK, pCXLE-hUL) were also subjected to a similar analysis (RT-PCR, Copy number analysis, karyotyping and Teratoma formation). As a result, epi-iPSCs were confirmed to be comparable to epi-iPSCs established by the use of the Y4 mixture (pCXLE-hOct4-shp53, pCXLE-hSK, pCXLE-hUL).
- a human iPS cell can be established and maintained even when a human dermal fibroblast (HDF) that has been used for transfection is used as feeder cells [ Takahashi et al., PLoSone, vol.4, issue 12, e8067 (2009 )].
- HDF human dermal fibroblast
- This is highly significant in considering clinical applications because the use of autologous feeder cells enables the maintenance of iPS cells under xeno-free conditions.
- the iPS cell used was a human iPS cell established by transferring pCXLE-hOct4-shp53, pCXLE-hSK and pCXLE-hUL to HDF.
- the culture broth used was a medium prepared by adding bFGF (Wako) to an ordinary primate ES cell culture medium (ReproCELL) at 4 ng/mL (hereinafter ReproCELL medium). Photographs of cells after 1 passage are shown in Fig. 25 . The ES-like morphology was maintained to an equivalent extent compared with the use of MSTO as feeder cells.
- iPS cells were maintained under completely xeno-free conditions using the xeno-free medium TeSR2 (Stemcell Technologies) and the xeno-free plate coating agent CELLstart (GIBCO) (no feeder cells used).
- the iPS cell used was a human iPS cell established by transferring pCXLE-hOct4-shp53, pCXLE-hSK and pCXLE-hUL to HDF. Photographs of cells after 1 passage are shown in Fig. 26 . When the ReproCELL medium was used, the cells began to change their morphology, whereas when TeSR2 was used, the cells maintained the undifferentiated morphology.
- the iPS cell used was a human iPS cell established by transferring pCXLE-hOct4-shp53, pCXLE-hSK and pCXLE-hUL to HDF. Photographs of cells after 1 passage are shown in Fig. 27 . Whichever xeno-free media were used, the ES-like morphology was maintained.
- pCXLE-EGFP was transferred to DP74 using Microporator.
- the xeno-free medium used was StemPro MSC-SFM (Invitrogen).
- DP74 was cultured and maintained at 37°C in the presence of 5% CO 2 in a CELLstart-coated 100 mm culture dish using StemPro MSC-SFM (Invitrogen) as a culture broth.
- StemPro MSC-SFM Invitrogen
- the medium was removed, and the cells were washed by the addition of 5 mL of PBS.
- the xeno-free cell dissociation solution TripLE select (Invitrogen) was added, and a reaction was carried out at 37°C for about 5 minutes. After the cells rose, StemPro MSC-SFM was added to suspend the cells, and the cells were recovered in a 15 mL centrifugal tube.
- the suspension was centrifuged at 800 rpm for 5 minutes, and the supernatant was removed. After the cells were again suspended in StemPro MSC-SFM, 6x10 5 cells were recovered in a 1.5 mL tube. The suspension was centrifuged at 800 rpm for 5 minutes, and the supernatant was removed.
- pCXLE-EGFP (3 ⁇ g) was transferred to the cells using Microporator. This transfer took place using a 100 ⁇ L chip with one pulse at 1850 V for 20 ms, or with two pulses at 1200 V for 30 ms.
- the transfected cells were transferred to a CELLstart-coated 6-well culture plate (Falcon) containing 3 mL of StemPro MSC SFM, and cultured at 37°C in the presence of 5% CO 2 for 7 days.
- the results are shown in Fig. 28 .
- the xeno-free medium StemPro MSC-SFM
- the transfer efficiency was low under the conditions of 1850 V, 20 ms, 1 pulse.
- the conditions were changed to 1200 V, 30 ms, 2 pulses, the cell survival rate and transfer efficiency increased.
- the latter conditions were employed for the transfection that followed.
- the three different plasmids pCXLE-hOct4-shp53, pCXLE-hSK and pCXLE-hUL were used for reprogramming.
- the dental pulp stem cell line DP74 was used.
- the DP74 line was cultured and maintained at 37°C in the presence of 5% CO 2 in a CELLstart-coated 100 mm culture dish using StemPro MSC-SFM as a culture broth.
- the medium was removed, and the cells were washed by the addition of 5 mL of PBS.
- TripLE select Invitrogen
- StemPro MSC-SFM was added to suspend the cells, and the cells were recovered in a 15 mL centrifugal tube. The suspension was centrifuged at 800 rpm for 5 minutes, and the supernatant was removed. After the cells were again suspended in StemPro MSC-SFM, 6x10 5 cells were recovered in a 1.5 mL tube. The suspension was centrifuged at 800 rpm for 5 minutes, and the supernatant was removed. The three different plasmids (1 ⁇ g each, 3 ⁇ g in total) were transferred to the cells using Microporator. This transfer took place using a 100 ⁇ L chip with two pulses at 1200 V for 30 ms.
- the transfected cells were transferred to a CELLstart-coated 6-well culture plate (Falcon) containing 3 mL of StemPro MSC-SFM, and cultured at 37°C in the presence of 5% CO 2 for 7 days. The medium was then removed, and the cells were washed by the addition of 2 mL of PBS. After removing the PBS, TripLE select (Invitrogen) was added, and a reaction was carried out at 37°C for about 5 minutes. After the cells rose, StemPro MSC-SFM was added to suspend the cells, and the cells were recovered into a 15 mL centrifugal tube. The suspension was centrifuged at 800 rpm for 5 minutes, and the supernatant was removed.
- CELLstart-coated 6-well culture plate Falcon
- StemPro MSC-SFM TripLE select
- Three microgram of expression plasmids (one microgram of pCXLE-hOct4-shp53, pCXLE-hSK and pCXLE-hUL) were electroporated into freshly isolated peripheral mononuclear cells (5.0x10 6 ) with Nucleofector (Lonza) with Human T cell kit according to the manufacturer's instructions. We used condition of program V-24. Six hours later, transfected blood cells were stimulated with cytokines (IL-6, sIL-6R, SCF, TPO, Flit3/4-ligand, and IL-2) and anti-CD3/CD28 antibodies. After 2 days, the cells were seeded onto 6-well plate covered with MEF feeder.
- cytokines IL-6, sIL-6R, SCF, TPO, Flit3/4-ligand, and IL-2
- Fig.36a Colonies were photographed on day 29 ( Fig.36b ). We could establish human iPS colonies that had a flat hESC-like morphology.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (14)
- Verfahren zum Produzieren einer iPS-Zelle, umfassend Inkontaktbringen einer somatischen Zelle in vitro mit (a) Oct3/4, oder einer Nukleinsäure welche selbiges codiert, (b) Klf4, oder einer Nukleinsäure welche selbiges codiert, (c) Sox2, oder einer Nukleinsäure welche selbiges codiert, (d) L-Myc, oder einer Nukleinsäure welche selbiges codiert, (e) einem funktionalen p53-Inhibitor, und (f) Lin28 oder Lin28b, oder einer Nukleinsäure welche selbige(s) codiert.
- Verfahren gemäß Anspruch 1, umfassend Übertragen von (a) einer Nukleinsäure, welche Oct3/4 codiert, (b) einer Nukleinsäure, welche Klf4 codiert, (c) einer Nukleinsäure, welche Sox2 codiert, (d) einer Nukleinsäure welche L-Myc codiert, (e) einem funktionalen p53-Inhibitor, und (f) einer Nukleinsäure, welche Lin28 oder Lin28b codiert, in eine somatische Zelle.
- iPS-Zell-Induktion-förderndes Agens, umfassend (a) eine Nukleinsäure, welche Oct3/4 codiert, (b) eine Nukleinsäure, welche Klf4 codiert, (c) eine Nukleinsäure, welche Sox2 codiert, (d) eine Nukleinsäure, welche L-Myc codiert, (e) einen funktionalen p53-Inhibitor, und (f) eine Nukleinsäure, welche Lin28 oder Lin28b codiert.
- Verfahren gemäß Anspruch 1 oder 2 oder Agens gemäß Anspruch 3, wobei der funktionale p53-Inhibitor ausgewählt wird aus der Gruppe bestehend aus einer siRNA gegen p53, einer shRNA gegen p53, einer DNA, welche eine siRNA oder shRNA gegen p53 codiert, und einer Nukleinsäure, welche eine dominant-negative Mutante von p53 codiert.
- Verfahren gemäß Anspruch 2 oder 4 oder Agens gemäß Anspruch 3 oder 4, wobei mindestens eine Nukleinsäure ausgewählt aus der Gruppe bestehend aus den vorstehenden (a), (b), (c), (d) und (f) in der Form eines episomalen Vektors übertragen wird.
- Verfahren oder Agens gemäß Anspruch 5, wobei der episomale Vektor ein sich-selbst-beseitigender (self-removal) Vektor ist, welcher von der iPS-Zelle zum Zeitpunkt der 5. Passage mit einer Frequenz von 50% oder mehr abgestoßen wird.
- Verfahren oder Agens gemäß Anspruch 5 oder 6, wobei mindestens (d) und (f) im selben episomalen Vektor miteingeschlossen sind, und polycystronisch in der Reihenfolge von (d) und (f) in der Ausrichtung von 5' zu 3' verbunden sind.
- Verfahren oder Agens gemäß Anspruch 5 oder 6, wobei die Anzahl der Arten von episomalen Vektoren, welche in die somatische Zelle eingebracht werden, mindestens drei oder mehr ist, wobei (a) in einer ersten Art von Vektor integriert ist, (b) und (c) in einer zweiten Art von Vektor integriert sind, sowie (d) und (f) in einer dritten Art von Vektor integriert sind.
- Verfahren oder Agens gemäß irgendeinem der Ansprüche 5 bis 8, wobei der episomale Vektor loxP-Sequenzen, platziert in der gleichen Orientierung, an den 5' und 3' Seiten eines Vektorbestandteils hat, welcher essentiell für die Replikation der Nukleinsäure ist.
- Verfahren gemäß irgendeinem der Ansprüche 1 bis 2 oder 4 bis 9 oder Agens gemäß irgendeinem der Ansprüche 3 bis 9, wobei die somatische Zelle oder iPS-Zelle eine humane Zelle ist.
- Verfahren gemäß Anspruch 10, umfassend Kultivieren einer Zelle in Absenz eines Bestandteils von einem nichthumanen Tier während des Zeitraums vom Kontakt der vorstehenden Faktoren (a) bis (f) mit der somatischen Zelle, bis zur Etablierung einer iPS-Zelle.
- Verfahren gemäß Anspruch 11, wobei humane Zellen als Feeder-Zellen verwendet werden, oder wobei keine Feeder-Zellen verwendet werden.
- Verfahren gemäß Anspruch 12, wobei die Feeder-Zellen vom selben Individuum abgeleitet sind wie die somatischen Zellen.
- Verfahren gemäß irgendeinem der Ansprüche 1 bis 2 oder 4 bis 13, wobei die verwendeten nuklearen Reprogrammierungs-Substanzen Nanog, oder eine Nukleinsäure, welche selbiges codiert, auschließen; oder das Agens gemäß irgendeinem der Ansprüche 3 bis 10, wobei das Agens eine Reprogrammierungs-Substanzen welche Nanog ist, oder eine Nukleinsäure, welche selbiges codiert, ausschließt.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23240209P | 2009-08-07 | 2009-08-07 | |
US30730610P | 2010-02-23 | 2010-02-23 | |
PCT/JP2010/063733 WO2011016588A1 (en) | 2009-08-07 | 2010-08-06 | Method of efficiently establishing induced pluripotent stem cells |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2462225A1 EP2462225A1 (de) | 2012-06-13 |
EP2462225A4 EP2462225A4 (de) | 2013-12-18 |
EP2462225B1 true EP2462225B1 (de) | 2019-03-06 |
Family
ID=43544479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10806584.8A Active EP2462225B1 (de) | 2009-08-07 | 2010-08-06 | Verfahren zur effizienten herstellung induzierter pluripotenter stammzellen |
Country Status (10)
Country | Link |
---|---|
US (2) | US8900871B2 (de) |
EP (1) | EP2462225B1 (de) |
JP (1) | JP5376478B2 (de) |
KR (1) | KR101774206B1 (de) |
CN (1) | CN102625837B (de) |
AU (1) | AU2010279913B2 (de) |
CA (1) | CA2770412C (de) |
ES (1) | ES2726766T3 (de) |
SG (2) | SG10201608797WA (de) |
WO (1) | WO2011016588A1 (de) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2933478T3 (es) | 2005-08-03 | 2023-02-09 | Astellas Inst For Regenerative Medicine | Métodos mejorados de reprogramación de células somáticas animales |
US20110061118A1 (en) * | 2008-03-17 | 2011-03-10 | Helmholtz Zentrum Munchen | Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination |
RU2010139426A (ru) * | 2008-03-17 | 2012-04-27 | Зе Скрипс Ресеч Инститьют (Us) | Комбинация химического и генетического подходов к получению индуцированных плюрипотентных стволовых клеток |
EP2307539B1 (de) * | 2008-07-30 | 2014-11-19 | Kyoto University | Verfahren zur effizienten herstellung induzierter pluripotenter stammzellen |
EP3312269A1 (de) | 2008-12-17 | 2018-04-25 | The Scripps Research Institute | Erzeugung und erhaltung von stammzellen |
WO2010098419A1 (en) | 2009-02-27 | 2010-09-02 | Kyoto University | Novel nuclear reprogramming substance |
ES2726766T3 (es) | 2009-08-07 | 2019-10-09 | Univ Kyoto | Método para el desarrollo eficiente de células madre pluripotentes inducidas |
JP5773393B2 (ja) | 2009-09-24 | 2015-09-02 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
JP5808331B2 (ja) | 2009-10-16 | 2015-11-10 | ザ スクリプス リサーチ インスティテュート | 多能性細胞の誘導法 |
JP5898086B2 (ja) | 2009-11-04 | 2016-04-06 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | 化学物質を用いるエピソームリプログラミング |
JP5765746B2 (ja) | 2010-02-16 | 2015-08-19 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
WO2011119942A1 (en) * | 2010-03-25 | 2011-09-29 | Vistagen Therapeutics, Inc. | Induction of ips cells using transient episomal vectors |
CN102959076B (zh) | 2010-03-31 | 2015-09-16 | 斯克里普斯研究所 | 重编程细胞 |
ES2685171T3 (es) | 2010-06-14 | 2018-10-05 | The Scripps Research Institute | Reprogramación de células a un nuevo destino |
EP2582794B2 (de) * | 2010-06-15 | 2024-04-24 | FUJIFILM Cellular Dynamics, Inc. | Erzeugung induzierter pluripotenter stammzellen aus kleinen volumina von peripherem blut |
US9447408B2 (en) | 2010-09-14 | 2016-09-20 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2012051515A2 (en) * | 2010-10-14 | 2012-04-19 | University Of Central Florida Research Foundation, Inc. | Cardiac induced pluripotent stem cells and methods of use in repair and regeneration of myocardium |
US9732319B2 (en) | 2010-12-22 | 2017-08-15 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
PL2694642T3 (pl) | 2011-04-08 | 2019-01-31 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposób odmładzania komórek |
US9758765B2 (en) | 2011-04-08 | 2017-09-12 | Osaka University | Modified laminin and use thereof |
WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
WO2013022022A1 (ja) * | 2011-08-08 | 2013-02-14 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
US20130157365A1 (en) * | 2011-12-20 | 2013-06-20 | Advanced Technologies And Regenerative Medicine, Llc | Induced pluripotent stem cells from human umbilical cord tissue-derived cells |
US20130157368A1 (en) * | 2011-12-20 | 2013-06-20 | Advanced Technologies And Regenerative Medicine, Llc | Induced pluripotent stem cells prepared from human kidney-derived cells |
US10119150B2 (en) * | 2012-05-13 | 2018-11-06 | Allele Biotechnology & Pharmaceuticals, Inc. | Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA |
US10155929B2 (en) * | 2012-05-13 | 2018-12-18 | Allele Biotechnology & Pharmaceuticals, Inc. | Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA |
ES2725827T3 (es) * | 2012-05-23 | 2019-09-27 | Univ Kyoto | Método altamente eficiente para establecer una célula madre pluripotencial artificial |
CN102965393B (zh) * | 2012-11-06 | 2015-08-26 | 上海交通大学 | 人诱导多能干细胞的制备方法及其用途 |
DK2951290T3 (en) | 2013-02-01 | 2018-01-22 | Us Health | PROCEDURE FOR PREPARING RETINAL PIGMENTAL EPIT (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) |
WO2014192312A1 (ja) * | 2013-05-31 | 2014-12-04 | 国立大学法人 東京医科歯科大学 | 正常な内向きのカリウム電流特性を有するiPS細胞由来心筋モデル細胞 |
WO2015006725A2 (en) | 2013-07-12 | 2015-01-15 | Cedars-Sinai Medical Center | Generation of induced pluripotent stem cells from normal human mammary epithelial cells |
CN103571794B (zh) * | 2013-07-19 | 2016-01-20 | 中国医学科学院血液病医院(血液学研究所) | 一种抑制PUMA功能改善iPS细胞建立功效的方法 |
CN103725710B (zh) * | 2013-12-25 | 2015-10-28 | 北京济福霖生物技术有限公司 | 一种可自我删除游离载体及其应用 |
CN103740756B (zh) * | 2013-12-25 | 2015-08-05 | 中国农业大学 | 一种可调控删除的非病毒游离载体及其构建方法 |
CN103740757B (zh) * | 2014-01-21 | 2016-04-20 | 中国科学院生物物理研究所 | 一种利用重编程制备猪神经干细胞的方法 |
CN104830906B (zh) * | 2014-02-12 | 2018-09-04 | 北京维通达生物技术有限公司 | 一种重编程获得功能性人肝脏实质细胞的方法 |
EP3805369A1 (de) | 2014-03-04 | 2021-04-14 | Fate Therapeutics, Inc. | Verbesserte neuprogrammierungsverfahren und zellkulturplattformen |
US10344285B2 (en) | 2014-04-09 | 2019-07-09 | Dna2.0, Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
KR20160145186A (ko) * | 2014-04-24 | 2016-12-19 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용 |
US20170107498A1 (en) * | 2014-06-05 | 2017-04-20 | Cedars-Sinai Medical Center | Novel and efficient method for reprogramming immortalized lymphoblastoid cell lines to induced pluripotent stem cells |
WO2016117139A1 (ja) * | 2015-01-20 | 2016-07-28 | タカラバイオ株式会社 | 神経系細胞の製造方法 |
JP2018509890A (ja) * | 2015-01-30 | 2018-04-12 | センター ナショナル ド ラ ルシェルシュ サイエンティフィーク | 人工多能性幹細胞(iPSC)の生産を再プログラムする方法 |
CN107787367B (zh) | 2015-04-06 | 2021-10-26 | 里兰斯坦福初级大学理事会 | 用于crispr/cas介导的基因调控的化学修饰的引导rna |
US11020463B2 (en) | 2015-08-07 | 2021-06-01 | The J. David Gladstone Institutes | Method of determining cellular protein homeostasis |
ES2903442T3 (es) | 2015-09-08 | 2022-04-01 | Fujifilm Cellular Dynamics Inc | Purificación basada en MACS del epitelio pigmentario de la retina derivado de células madre |
AU2016321170B2 (en) | 2015-09-08 | 2022-09-01 | Fujifilm Cellular Dynamics | Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells |
LT3359671T (lt) | 2015-10-08 | 2021-12-10 | Dna Twopointo Inc. | Dnr vektoriai, transpozonai ir transpozazės, skirti eukariotinio genomo modifikacijai |
AU2016338680B2 (en) | 2015-10-16 | 2022-11-17 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
WO2017070337A1 (en) | 2015-10-20 | 2017-04-27 | Cellular Dynamics International, Inc. | Methods for directed differentiation of pluripotent stem cells to immune cells |
AU2017254268B2 (en) | 2016-04-22 | 2023-03-16 | Kyoto University | Method for producing dopamine-producing neural precursor cells |
CN109641020B (zh) * | 2016-04-29 | 2022-09-02 | 复诺健生物科技加拿大有限公司 | 在癌细胞中具有增强复制的hsv载体 |
GB201608944D0 (en) * | 2016-05-20 | 2016-07-06 | Ospedale San Raffaele And Fond Telethon | Gene Tharapy |
US11572545B2 (en) | 2016-06-16 | 2023-02-07 | Cedars-Sinai Medical Center | Efficient method for reprogramming blood to induced pluripotent stem cells |
US10221395B2 (en) | 2016-06-16 | 2019-03-05 | Cedars-Sinai Medical Center | Efficient method for reprogramming blood to induced pluripotent stem cells |
US20180030478A1 (en) | 2016-07-01 | 2018-02-01 | Research Development Foundation | Elimination of proliferating cells from stem cell-derived grafts |
EP3491134B1 (de) | 2016-08-01 | 2023-10-11 | University of Pittsburgh - of The Commonwealth System of Higher Education | Menschliche induzierte pluripotente stammzellen zur hocheffizienten genmanipulation |
EP3510151A4 (de) | 2016-09-09 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | Hochdurchsatz-präzisionsgenomeditierung |
CN110050061A (zh) | 2016-10-05 | 2019-07-23 | 富士胶片细胞动力公司 | 从具有MeCP2破坏的诱导多能干细胞生成成熟谱系 |
JP7212615B2 (ja) * | 2016-10-05 | 2023-01-25 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 多能性幹細胞からhlaホモ接合免疫細胞への指向分化方法 |
US11458225B2 (en) | 2016-11-09 | 2022-10-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 3D vascularized human ocular tissue for cell therapy and drug discovery |
WO2018144546A1 (en) * | 2017-02-01 | 2018-08-09 | President And Fellows Of Harvard College | Methods for increasing efficiency of gene editing in cells |
CN106939299B (zh) * | 2017-02-04 | 2022-11-15 | 滨州医学院 | microRNA重编程体细胞为神经干细胞的制备方法及应用 |
US11530388B2 (en) | 2017-02-14 | 2022-12-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of engineering human induced pluripotent stem cells to produce liver tissue |
JP7181219B2 (ja) | 2017-04-18 | 2022-11-30 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 抗原特異的免疫エフェクター細胞 |
WO2018232079A1 (en) | 2017-06-14 | 2018-12-20 | Daley George Q | Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer |
JP2021521792A (ja) | 2018-04-20 | 2021-08-30 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 眼球細胞の分化方法及びその使用 |
WO2020106622A1 (en) | 2018-11-19 | 2020-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biodegradable tissue replacement implant and its use |
WO2020113029A2 (en) | 2018-11-28 | 2020-06-04 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
KR20210096648A (ko) | 2018-11-29 | 2021-08-05 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 자연 살해 세포의 생체외 확장을 위한 방법 및 이의 용도 |
CN109679918A (zh) * | 2018-12-25 | 2019-04-26 | 合肥中科干细胞再生医学有限公司 | 一种便捷的人诱导性多能干细胞的制备方法 |
CN109666650A (zh) * | 2019-01-04 | 2019-04-23 | 北京航空航天大学 | 一种细胞重编程方法 |
CN109913494A (zh) * | 2019-02-12 | 2019-06-21 | 北京呈诺医学科技有限公司 | 一种新的ips细胞的诱导方法 |
IL294715A (en) | 2020-01-23 | 2022-09-01 | Childrens Medical Ct Corp | Inducible t-cell differentiation from human pluripotent stem cells |
US20230055044A1 (en) * | 2020-01-24 | 2023-02-23 | I Peace, Inc. | Method for manufacturing induced pluripotent stem cells |
KR20230019453A (ko) | 2020-05-29 | 2023-02-08 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 망막 색소 상피 세포 및 광수용체의 이중 세포 응집체 및 이의 사용 방법 |
CN116323677A (zh) | 2020-05-29 | 2023-06-23 | 富士胶片细胞动力公司 | 视网膜色素上皮和光感受器双层及其用途 |
CN116829721A (zh) * | 2020-07-20 | 2023-09-29 | 细胞研究私人有限公司 | 一种产生诱导多能干细胞的方法、诱导多能干细胞和使用所述诱导多能干细胞的方法 |
CN114149974A (zh) * | 2020-09-08 | 2022-03-08 | 是光隽恒(北京)生物科技有限公司 | 诱导间充质干细胞成为多能干细胞的方法 |
IL302728A (en) | 2020-11-13 | 2023-07-01 | Catamaran Bio Inc | Genetically modified natural killer cells and methods of using them |
US20220162288A1 (en) | 2020-11-25 | 2022-05-26 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
GB202101107D0 (en) * | 2021-01-27 | 2021-03-10 | Oxford Genetics Ltd | Method of genome editing |
US20220389436A1 (en) | 2021-05-26 | 2022-12-08 | FUJIFILM Cellular Dynamics, Inc. | Methods to prevent rapid silencing of genes in pluripotent stem cells |
CA3220433A1 (en) | 2021-05-28 | 2022-12-01 | Arvydas Maminishkis | Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells |
JP2024520424A (ja) | 2021-05-28 | 2024-05-24 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 黄斑、中心および末梢網膜色素上皮細胞を生成する方法 |
WO2023039586A1 (en) | 2021-09-10 | 2023-03-16 | Agilent Technologies, Inc. | Guide rnas with chemical modification for prime editing |
KR20240056604A (ko) | 2021-09-13 | 2024-04-30 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 수임 심장 전구세포의 제조 방법 |
CN113862221B (zh) * | 2021-10-27 | 2024-04-30 | 上海爱萨尔生物科技有限公司 | 外周血单个核细胞的培养液及培养方法 |
US20240003871A1 (en) | 2022-06-29 | 2024-01-04 | FUJIFILM Cellular Dynamics, Inc. | Ipsc-derived astrocytes and methods of use thereof |
CN115044590B (zh) * | 2022-06-30 | 2023-08-15 | 昆明理工大学 | p53基因突变体及其表达的蛋白在制备诊断和治疗肥厚型心肌病的药物中的应用 |
WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
NZ513487A (en) | 1999-01-29 | 2003-02-28 | Univ Illinois | The use of a P53 inhibitor for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant |
ATE367445T1 (de) | 1999-05-18 | 2007-08-15 | Dnavec Research Inc | Viraler paramyxoviridae vektor mit einem defekten hüllprotein-gen |
EP1859026A2 (de) | 2005-01-31 | 2007-11-28 | ES Cell International Pte Ltd. | Gerichtete differenzierung embryonaler stammzellen und verwendungen davon |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
CN103113463B (zh) | 2005-12-13 | 2015-02-18 | 国立大学法人京都大学 | 核重新编程因子 |
EP1981970A4 (de) * | 2006-01-11 | 2009-10-21 | Technion Res & Dev Foundation | Von einer menschlichen embryonalen stammzelle abgeleitete bindegewebe-vorläufer zur geweberekonstruktion |
US8440461B2 (en) | 2007-03-23 | 2013-05-14 | Wisconsin Alumni Research Foundation | Reprogramming somatic cells using retroviral vectors comprising Oct-4 and Sox2 genes |
WO2008144580A2 (en) * | 2007-05-17 | 2008-11-27 | Oregon Health & Science University | Primate stem cells produced by somatic cell nuclear transfer |
AU2008297024B2 (en) * | 2007-10-31 | 2014-08-28 | Kyoto University | Nuclear reprogramming method |
KR101532442B1 (ko) | 2007-12-10 | 2015-06-29 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 효율적인 핵 초기화 방법 |
US20110061118A1 (en) | 2008-03-17 | 2011-03-10 | Helmholtz Zentrum Munchen | Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination |
CN101550406B (zh) | 2008-04-03 | 2016-02-10 | 北京大学 | 制备多潜能干细胞的方法,试剂盒及用途 |
KR101648019B1 (ko) | 2008-06-04 | 2016-08-16 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | 비-바이러스 접근법을 사용한 iPS 세포의 생산 방법 |
JP2011524174A (ja) * | 2008-06-13 | 2011-09-01 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | 細胞のプログラミングおよび再プログラミング |
CN101835890B (zh) | 2008-06-27 | 2013-07-24 | 国立大学法人京都大学 | 有效建立诱导的多能干细胞的方法 |
EP2307539B1 (de) | 2008-07-30 | 2014-11-19 | Kyoto University | Verfahren zur effizienten herstellung induzierter pluripotenter stammzellen |
JP5553178B2 (ja) | 2008-07-31 | 2014-07-16 | 国立大学法人岐阜大学 | 効率的な人工多能性幹細胞の樹立方法 |
US20110003365A1 (en) | 2009-05-29 | 2011-01-06 | Kyoto University | Method of preparing induced pluripotent stem cells deprived of reprogramming gene |
ES2726766T3 (es) | 2009-08-07 | 2019-10-09 | Univ Kyoto | Método para el desarrollo eficiente de células madre pluripotentes inducidas |
CN102803476A (zh) | 2009-09-14 | 2012-11-28 | 程临钊 | 血细胞重编程产生多潜能干细胞和多功能干细胞 |
JP5765746B2 (ja) | 2010-02-16 | 2015-08-19 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
WO2011119942A1 (en) | 2010-03-25 | 2011-09-29 | Vistagen Therapeutics, Inc. | Induction of ips cells using transient episomal vectors |
CA2806858C (en) | 2010-08-04 | 2021-06-15 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
WO2013022022A1 (ja) | 2011-08-08 | 2013-02-14 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
ES2725827T3 (es) | 2012-05-23 | 2019-09-27 | Univ Kyoto | Método altamente eficiente para establecer una célula madre pluripotencial artificial |
-
2010
- 2010-08-06 ES ES10806584T patent/ES2726766T3/es active Active
- 2010-08-06 JP JP2012523493A patent/JP5376478B2/ja active Active
- 2010-08-06 KR KR1020127004663A patent/KR101774206B1/ko active IP Right Grant
- 2010-08-06 AU AU2010279913A patent/AU2010279913B2/en active Active
- 2010-08-06 SG SG10201608797WA patent/SG10201608797WA/en unknown
- 2010-08-06 EP EP10806584.8A patent/EP2462225B1/de active Active
- 2010-08-06 WO PCT/JP2010/063733 patent/WO2011016588A1/en active Application Filing
- 2010-08-06 US US13/389,359 patent/US8900871B2/en active Active
- 2010-08-06 CA CA2770412A patent/CA2770412C/en active Active
- 2010-08-06 CN CN201080035155.9A patent/CN102625837B/zh active Active
- 2010-08-06 SG SG2012006862A patent/SG178197A1/en unknown
-
2014
- 2014-11-04 US US14/533,080 patent/US9404124B2/en active Active
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
EP2462225A1 (de) | 2012-06-13 |
JP2013501505A (ja) | 2013-01-17 |
ES2726766T3 (es) | 2019-10-09 |
SG178197A1 (en) | 2012-03-29 |
US8900871B2 (en) | 2014-12-02 |
EP2462225A4 (de) | 2013-12-18 |
KR101774206B1 (ko) | 2017-09-04 |
US20120196360A1 (en) | 2012-08-02 |
CN102625837B (zh) | 2015-01-14 |
AU2010279913A1 (en) | 2012-03-15 |
AU2010279913B2 (en) | 2016-04-28 |
CA2770412C (en) | 2018-09-11 |
CN102625837A (zh) | 2012-08-01 |
JP5376478B2 (ja) | 2013-12-25 |
US9404124B2 (en) | 2016-08-02 |
SG10201608797WA (en) | 2016-12-29 |
CA2770412A1 (en) | 2011-02-10 |
KR20120047968A (ko) | 2012-05-14 |
US20150140662A1 (en) | 2015-05-21 |
WO2011016588A1 (en) | 2011-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2462225B1 (de) | Verfahren zur effizienten herstellung induzierter pluripotenter stammzellen | |
EP2288692B1 (de) | Verfahren zur effizienten herstellung induzierter pluripotenter stammzellen | |
EP2853592B1 (de) | Hochleistungsverfahren zur herstellung von künstlichen pluripotenten stammzellen | |
US9447408B2 (en) | Method of efficiently establishing induced pluripotent stem cells | |
WO2011094738A1 (en) | Enhanced efficiency of induced pluripotent stem cell generation | |
US10077429B2 (en) | Method of efficiently establishing induced pluripotent stem cells | |
JP5682043B2 (ja) | 安全な多能性幹細胞の選択方法 | |
JP6676260B2 (ja) | 効率的な人工多能性幹細胞の樹立方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120224 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20131115 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/10 20060101ALI20131111BHEP Ipc: C12N 15/09 20060101AFI20131111BHEP Ipc: C12N 15/85 20060101ALI20131111BHEP |
|
17Q | First examination report despatched |
Effective date: 20141126 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/074 20100101ALI20180703BHEP Ipc: C12N 15/85 20060101ALI20180703BHEP Ipc: C12N 15/09 20060101AFI20180703BHEP Ipc: C12N 5/10 20060101ALI20180703BHEP |
|
INTG | Intention to grant announced |
Effective date: 20180801 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
INTG | Intention to grant announced |
Effective date: 20190123 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1104577 Country of ref document: AT Kind code of ref document: T Effective date: 20190315 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010057431 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOHEST AG, CH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190606 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190607 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190606 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1104577 Country of ref document: AT Kind code of ref document: T Effective date: 20190306 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2726766 Country of ref document: ES Kind code of ref document: T3 Effective date: 20191009 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190706 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010057431 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190706 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 |
|
26N | No opposition filed |
Effective date: 20191209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190806 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190806 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20100806 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230508 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230825 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230727 Year of fee payment: 14 Ref country code: GB Payment date: 20230816 Year of fee payment: 14 Ref country code: ES Payment date: 20230907 Year of fee payment: 14 Ref country code: CH Payment date: 20230902 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20230811 Year of fee payment: 14 Ref country code: FR Payment date: 20230710 Year of fee payment: 14 Ref country code: DE Payment date: 20230816 Year of fee payment: 14 Ref country code: BE Payment date: 20230717 Year of fee payment: 14 |